0001493152-17-008961.txt : 20170811 0001493152-17-008961.hdr.sgml : 20170811 20170811151936 ACCESSION NUMBER: 0001493152-17-008961 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170811 DATE AS OF CHANGE: 20170811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 171024706 BUSINESS ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from ______________ to ______________

Commission file number 0-21617

ProPhase Labs, Inc.

(Exact name of registrant as specified in its charter)

Delaware		23-2577138
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

621 N. Shady Retreat Road, Doylestown, Pennsylvania		18901
(Address of principal executive office)		(Zip Code)

(215) 345-0919

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (See definition of “large accelerated filer”, “accelerated filer”, “non-accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]	Accelerated filer [ ]	Non-accelerated filer [ ]	Smaller reporting company [X]
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at August 11, 2017
Common Stock, $0.0005 par value		16,166,796

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

		PAGE
*PART I.*	*FINANCIAL INFORMATION*

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016	3

	Condensed Consolidated Statements of Operations for the Three Months Ended and Six Months Ended June 30, 2017 and 2016 (unaudited)	4

	Condensed Consolidated Statement of Stockholders’ Equity for the Six Months Ended June 30, 2017 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016 (unaudited)	6

	Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29

Item 4.	Controls and Procedures	29

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	30

Item 1A.	Risk Factors	30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31

Item 3.	Defaults Upon Senior Securities	31

Item 4.	Mine Safety Disclosures	31

Item 5.	Other Information	31

Item 6.	Exhibits	32

Signatures		33

Certifications

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	June 30, 2017			December 31, 2016
	(unaudited)
ASSETS
Cash and cash equivalents (Note 2)	$	37,280		$	441
Accounts receivable, net (Note 2)		1,835			5,770
Inventory (Note 2)		1,966			2,736
Prepaid expenses and other current assets (Note 2)		849			680
Assets held for sale (Note 3)		294			-
Total current assets		42,224			9,627

Property, plant and equipment, net of accumulated depreciation of $5,274 and $5,134, respectively (Note 2)		2,875			3,175
Escrow receivable		5,000			-
Total assets	$	50,099		$	12,802

LIABILITIES AND STOCKHOLDERS’ EQUITY
LIABILITIES
Secured promissory notes, net (Note 4)	$	-		$	1,490
Accounts payable		916			2,156
Accrued advertising and other allowances (Note 2)		1,551			2,805
Other current liabilities		289			389
Due to Mylan, Inc. and affiliates (Note 3)		717			-
Total current liabilities		3,473			6,840

COMMITMENTS AND CONTINGENCIES (Note 7)		-			-

STOCKHOLDERS’ EQUITY

Preferred stock, authorized 1,000,000, $.0005 par value, no shares issued (Note 5)		-			-
Common stock, $.0005 par value; authorized 50,000,000; issued: 26,454,593 and 26,313,593 shares, respectively (Note 5)		13			13
Additional paid-in-capital		56,567			56,378
Retained earnings (Accumulated deficit)		22,646			(19,687	)
Treasury stock, at cost, 10,294,797 and 9,232,817 shares (Note 5)		(32,600	)		(30,742	)
Total stockholders’ equity		46,626			5,962
Total liabilities and stockholders’ equity	$	50,099		$	12,802

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended						Six Months Ended
	June 30, 2017			June 30, 2016			June 30, 2017			June 30, 2016

Net sales (Note 2)	$	1,905		$	1,021		$	2,676		$	2,037

Cost of sales (Note 2)		1,765			993			2,451			1,723

Gross profit		140			28			225			314

Operating expenses (Note 2):
Sales and marketing		221			236			336			534
Administration		1,306			943			2,387			2,146
Research and development		224			121			258			160
		1,751			1,300			2,981			2,840
Other income (expense), net		151			(53	)		97			(105	)

Loss from continuing operations before income taxes (Note 6)		(1,460	)		(1,325	)		(2,659	)		(2,631	)

Income tax benefit from continuing operations		-			-			18,123			-

Income (loss) from continuing operations		(1,460	)		(1,325	)		15,464			(2,631	)

Discontinued operations (Note 3):
Income (loss) from discontinued operations		(835	)		198			530			168
Gain on sale of discontinued operations, net of taxes		(10	)		-			26,339			-

Income (loss) from discontinued operations		(845	)		198			26,869			168

Net income (loss)	$	(2,305	)	$	(1,127	)	$	42,333		$	(2,463	)

Basic earnings (loss) per share:
Income (loss) from continuing operations	$	(0.09	)	$	(0.08	)	$	0.91		$	(0.15	)
Income (loss) from discontinued continued operations		(0.05	)		0.01			1.58			0.01
Net income (loss)	$	(0.14	)	$	(0.07	)	$	2.49		$	(0.14	)

Diluted earnings (loss) per share:
Income (loss) from continuing operations	$	(0.09	)	$	(0.08	)	$	0.87		$	(0.15	)
Income (loss) from discontinued continued operations		(0.05	)		0.01			1.52			0.01
Net income (loss)	$	(0.14	)	$	(0.07	)	$	2.39		$	(0.14	)

Weighted average common shares outstanding:
Basic		16,943			17,081			17,030			17,081
Diluted		16,943			17,081			17,680			17,081

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statement of

Stockholders’ Equity

(in thousands, except share data)

(unaudited)

	Common Stock Shares
	Outstanding, Net of Shares of Treasury			Par		Additional Paid-In			Retained Earnings			Treasury
	Stock			Value		Capital			(Accum. Deficit)			Stock			Total

Balance at December 31, 2016		17,080,776		$	13	$	56,378		$	(19,687	)	$	(30,742	)	$	5,962

Net income										42,333						42,333

Proceeds from warrants exercised		51,000			0		69									69
Proceeds from options exercised		90,000					102									102

Treasury stock acquired		(1,061,980	)										(1,858	)		(1,858	)

Share-based compensation expense							18									18

Tax benefit from exercise of warrants and options							43									43
Tax benefit allowance							(43	)								(43	)

Balance at June 30, 2017		16,159,796		$	13	$	56,567		$	22,646		$	(32,600	)	$	46,626

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Six Months Ended
	June 30, 2017			June 30, 2016

Cash flows from operating activities:
Net income (loss)	$	42,333		$	(2,463	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Gain on sale of assets, net of taxes		(26,339	)		-
Change in valuation allowance, income tax		(19,473	)		-
Depreciation and amortization		419			213
Amortization of loan origination and warrant expenses		10			12
Share-based compensation expense		18			1
Changes in operating assets and liabilities:
Accounts receivable		3,935			2,199
Inventory		770			(18	)
Prepaid and other assets		(169	)		703
Accounts payable		(1,240	)		382
Accrued advertising and other allowances		(1,254	)		(621	)
Due to Mylan, Inc. and affiliates		717			-
Other current liabilities		(100	)		(596	)
Assets held for sale, discontinued operations		(294	)		-
Net cash used in operating activities		(667	)		(188	)

Cash flows from investing activities:
Net proceeds from the sale of asset		40,825			-
Capital expenditures		(132	)		(327	)
Net cash provided by (used in) investing activities		40,693			(327	)

Cash flows from financing activities:
Payments to retire Notes		(1,500	)		-
Payments to acquire treasury stock		(1,858	)		-
Proceeds from exercise of warrants and stock options		171			-
Net cash used in financing activities		(3,187	)		-

Net increase (decrease) in cash and cash equivalents		36,839			(515	)

Cash and cash equivalents at beginning of period		441			1,664

Cash and cash equivalents at end of period	$	37,280		$	1,149

Supplemental disclosures of cash flow information:

Interest paid	$	54		$	95

Income taxes paid	$	1,350		$	-

Non-cash investing activities:
Escrow receivable	$	5,000		$	-

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Business

ProPhase Labs, Inc. (“we”, “us” or the “Company”) was initially organized in Nevada in July 1989. Effective June 18, 2015, we changed our state of incorporation from the State of Nevada to the State of Delaware. We are a manufacturer, marketer and distributor of a diversified range of health care and cold remedy products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug and natural base health products including supplements, personal care and cosmeceutical products.

Discontinued Operations

Prior to March 29, 2017, our flagship OTC drug brand was Cold-EEZE^® and our principal product was Cold-EEZE^®cold remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold. In addition to Cold-EEZE^® cold remedy lozenges, we also marketed and distributed non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® cold remedy QuickMelts^®, (ii) Cold-EEZE^®Gummies and (iii) Cold-EEZE^® cold remedy Oral Spray. Each of the Cold-EEZE^® QuickMelts^®and Gummies products are based on a proprietary zinc gluconate formulation in combination with certain (i) immune system support, (ii) energy, (iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients.

On January 6, 2017, we signed an asset purchase agreement (as amended, the “Asset Purchase Agreement”), by and among the Company, Meda Consumer Healthcare Inc. (“MCH”) and Mylan Inc. (together with MCH, “Mylan”), for the sale of assets by us to Mylan (see Note 3). The sale of assets (i) was subject to stockholder approval and other customary closing conditions and (ii) consisted principally of the sale of our intellectual property rights and other assets relating to our Cold-EEZE^®brand and product line (collectively, referred to herein as the “Cold-EEZE^® Business”) to Mylan, including all current and pipeline over-the-counter allergy, cold, flu, multi-symptom relief and immune support treatments for adults and children to the extent each is, or is intended to be, branded “Cold-EEZE^®”, and all private label versions thereof, including all formulations and derivatives thereof as set forth in the Asset Purchase Agreement.

A special meeting of our stockholders was held on March 29, 2017 (the “Special Meeting”). At the Special Meeting, our stockholders approved the sale of assets and the transactions contemplated by the Asset Purchase Agreement. Effective March 29, 2017, we completed the sale of the Cold-EEZE^®Business to Mylan. As a consequence of the sale of the Cold-EEZE^®Business, for the three and six months ended June 30, 2017 and 2016, we have classified as discontinued operations (i) the gain from the sale of the Cold-EEZE^® Business, (ii) all income and expenses attributable to the Cold-EEZE^®Business and (iii) the income tax expense attributed to the sale of the Cold-EEZE^® Business (see Notes 3 and 6). Excluded from the sale of the Cold-EEZE^®Business were our accounts receivable and inventory, and we also retained all liabilities associated with our Cold-EEZE^®Business operations arising prior to March 29, 2017.

Continuing Operations

We continue to own and operate our manufacturing facility and manufacturing business in Lebanon, Pennsylvania, and our headquarters in Doylestown, Pennsylvania. As part of the sale of the Cold-EEZE^® Business, we entered into a manufacturing agreement (see Note 7) with Mylan and our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), to supply various Cold-EEZE^® lozenge products to Mylan. In addition to the production services we provide to Mylan under the manufacturing agreement, we produce OTC drug and dietary supplement lozenges and other products for other third party customers in addition to performing operational tasks such as warehousing, customer order processing and shipping.

We are also pursuing a series of new product development and pre-commercialization initiatives in the OTC dietary supplement category. Initial OTC dietary supplement product development activities were completed in the fourth quarter of Fiscal 2015 under the brand name of TK Supplements^®. The TK Supplements^® product line comprises three men’s health products: (i) Legendz XL^® for sexual health, (ii) Triple Edge XL^®, a daily energy booster plus testosterone support, and (iii) Super ProstaFlow Plus^TM for prostate and urinary health. We recently completed a broad series of clinical studies which support important product claims which have now been incorporated in our product packaging and marketing communications. In addition to developing direct-to-consumer (“Direct Response”) marketing strategies of Legendz XL^®, we received initial product acceptance and shipped into a national chain drug retailer during the second quarter of Fiscal 2017. In addition, we have received initial product acceptance from several regional retailers to begin shipments in the third and fourth quarters of Fiscal 2017.

For the three and six months ended June 30, 2017 and 2016, our revenues from continuing operations have come principally from our OTC health care products.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Business – continued

We use a December 31 year-end for financial reporting purposes. References herein to “Fiscal 2017” shall mean the fiscal year ended December 31, 2017 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of operating results that may be achieved over the course of the full year. Historical financial statements have been reclassified to conform to the current period presentation, principally reflecting the sale of Cold-EEZE^® Business as discontinued operations.

Discontinued Operations Carve Out and ProPhase Allocations

For the three and six months ended June 30, 2017 and 2016, results from operations for our Cold-EEZE^® Business are classified as discontinued operations The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, net sales, cost of sales, operating expenses and interest expense associated with the Cold-EEZE^®Business’s operations. General administrative and overhead expenses, including personnel expenses and bonuses, and research and development overhead expenses incurred by us (for which the discontinued operation benefits from such resources) are allocated to discontinued operations based upon the percentage of the Cold-EEZE^® Business’s net sales to our consolidated net sales. For the three months ended June 30, 2017 and 2016, we allocated (i) zero and $319,000, respectively, of administrative expenses and (ii) zero and $48,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations. For the six months ended June 30, 2017 and 2016, we allocated (i) $348,000 and $656,000, respectively, of administrative expenses and (ii) $52,000 and $95,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations (see Note 3).

Seasonality of the Business

Our net sales are derived principally from our OTC heath care and cold remedy products sold in the United States of America. Our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net sales. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

For the three and six months ended June 30, 2017 and 2016, our net sales were principally related to domestic markets.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment, impairment of property and equipment, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Cash and Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2017 and December 31, 2016, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $1.7 million and $1.6 million, respectively. The components of inventory are as follows (in thousands):

	June 30, 2017		December 31, 2016
Raw materials	$	1,590	$	1,404
Work in process		342		466
Finished goods		34		866
	$	1,966	$	2,736

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements – ten to thirty-nine years; machinery and equipment – three to seven years; computer software – three years; and furniture and fixtures – five years.

Concentration of Risks

Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC health care products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2017, our cash balance was $37.3 million and our bank balance was $38.5 million. Of the total bank balance, $342,000 was covered by federal depository insurance and $38.1 million was uninsured at June 30, 2017.

Note 2 – Summary of Significant Accounting Policies – continued

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due to us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2017 and December 31, 2016.

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable, assets held for sale, accounts payable, accrued expenses and notes payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Pursuant to the terms of the Asset Purchase Agreement, we are responsible for and continue to accept product returns of the Cold-EEZE^®Business for product shipped prior to March 30, 2017. Additionally, pursuant to the terms of the Asset Purchase Agreement, we allocated and, in June 2017, issued a credit to Mylan in an aggregate of $400,000 for future sales returns and allowances arising from certain product returns that were sold by us prior to March 30, 2017.

As of June 30, 2017 and December 31, 2016, we included a provision for sales allowances of zero and $108,000, respectively. Additionally, accrued advertising and other allowances as of June 30, 2017 included (i) $934,000 for estimated future sales returns and (ii) $598,000 for cooperative incentive promotion costs. As of December 31, 2016, accrued advertising and other allowances included (i) $1.2 million for estimated future sales returns and (ii) $1.5 million for cooperative incentive promotion costs.

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred (i) from continuing operations for the three months ended June 30, 2017 and 2016 were $21,000 and $139,000, respectively, and (ii) attributed to and classified as discontinued operations were $205,000 and $471,000, respectively. Advertising and incentive promotion expenses incurred (i) from continuing operations for the six months ended June 30, 2017 and 2016 were $53,000 and $339,000 , respectively, and (ii) attributed to and classified as discontinued operations were $2.8 million and $3.3 million, respectively. Included in prepaid expenses and other current assets was $17,000 and $263,000 at June 30, 2017 and December 31, 2016, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling

Product sales may carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock-Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three and six months ended June 30, 2017 and 2016, we charged to operations $18,000 and $1,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs incurred for the three months ended June 30, 2017 and 2016 (i) from continuing operations were $224,000 and $121,000, respectively, and (ii) attributed to and classified as discontinued operations of zero and $48,000, respectively. Research and development costs incurred for the six months ended June 30, 2017 and 2016 (i) from continuing operations were $258,000 and $160,000, respectively, and (ii) attributed to and classified as discontinued operations of $52,000 and $95,000, respectively. Research and development costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until we have sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a full valuation allowance equaling the total deferred tax asset is being provided (see Notes 3 and 6).

Note 2 – Summary of Significant Accounting Policies – continued

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. This ASU, as amended, is effective for fiscal years and interim periods within those years beginning after December 15, 2017. We are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02 “Leases”. The new standard will require most leases to be recognized on the balance sheet which will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter of fiscal 2019 and mandates a modified retrospective transition method. We do not intend to early adopt and are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses.” The standard modifies the impairment model for most financial assets, including trade accounts receivables and loans, and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. The effective date of the standard is for fiscal years beginning after December 15, 2019 with early adoption permitted. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance will be effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted including adoption in an interim period. We do not intend to early adopt and we are currently assessing the impact of adoption of this update will have on our consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other than Inventory”. The new standard requires entities should recognize the income tax consequences of an asset other than inventory when the asset transfer occurs. The new guidance will be effective for fiscal years beginning after December 15, 2017 and requires a modified retrospective adoption through a cumulative effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Discontinued Operations, Sale of the Cold-EEZE^® Business

At the Special Meeting held on March 29, 2017, our stockholders approved the sale of the Cold-EEZE^® Business and the transactions contemplated by the Asset Purchase Agreement. Effective March 29, 2017, we completed the sale of the Cold-EEZE^®Business to Mylan.

As a consequence of the sale of the Cold-EEZE^® Business, for the three and six months ended June 30, 2017 and 2016, we have classified as discontinued operations (i) the gain from the sale of the Cold-EEZE^® Business, (ii) all gains and losses attributable to the Cold-EEZE^® Business operations and (iii) the income tax expense attributed to the sale of the Cold-EEZE^® Business (see Note 6). Excluded from the sale of the Cold-EEZE^®Business were our accounts receivable and inventory, and we also retained all liabilities associated with our Cold-EEZE^®Business operations arising prior to March 29, 2017.

Pursuant to the Asset Purchase Agreement, we also agreed to a one-time sale to Mylan of certain non-lozenge-based Cold-EEZE^® inventory. At June 30, 2017, we classified as assets held for sale approximately $294,000 of such inventory, which approximates our cost. At December 31, 2016, the balance sheet impact of discontinued operations was deemed not material, as such, no reclassifications for discontinued operations have been presented.

Pursuant to the Asset Purchase Agreement, we entered into a 90 day transition service arrangement with Mylan, for which we earned $150,000 in transition service fees through June 30, 2017. Pursuant to this arrangement, we (i) received, processed, fulfilled, and shipped customer orders, and billed such customers for these shipments on behalf of Mylan from March 30, 2017 to June 30, 2017, (ii) processed certain sales allowances, returns and other customer promotional deductions, and (iii) paid certain Cold-EEZE^® Business expenses which are to be reimbursed by Mylan. At June 30, 2017, we have a balance due to Mylan of $717,000 which is comprised of (i) net billings to Mylan’s customers for product shipments, less sales and other allowances, of $1.8 million (ii) return allocation of $400,000 for future sales returns and allowances (see Note 2), offset by (ii1) $1.4 million for product shipments and transition service fee due from Mylan and (iv) $106,000 for the reimbursement of certain Cold-EEZE^® Business expenses we paid on behalf of Mylan. For the three and six months ended June 30, 2017, the $150,000 transition service fees earned are recorded as a component of other income (expense).

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

The net proceeds received from the sale of the Cold-EEZE^® Business were as follows (in thousands):

	Amount
Gross consideration from the sale of the Cold-EEZE^®Business	$	50,000
Closing and transaction costs		(4,175	)
Net proceeds from sale of the Cold-EEZE^® Business		45,825
Book value of assets sold		(13	)
Gain on sale of the Cold-EEZE^® Business before income taxes		45,812
Income tax expense		(19,473	)
Gain on sale of the Cold-EEZE^® Business after income taxes	$	26,339

Net proceeds:
Cash paid at closing, net of closing and transaction costs	$	43,145
Proceeds due on sale of assets, cash held in escrow (see Note 8)		5,000
	$	48,145

For the three and six months ended June 30, 2017, we incurred $10,000 and $4.2 million in closing and transaction costs associated with the sale of the Cold-EEZE^® Business which were comprised of (i) transaction fees and related closing costs of $1.9 million and (ii) performance bonuses, contract termination compensation and severance payments to certain employees associated with the sale of the Cold-EEZE^® Business of $2.3 million. The compensation committee of our board of directors approved these compensation arrangements. These compensation and termination payments were paid by us in April 2017.

Note 3 – Discontinued Operations, Sale of the Cold-EEZE^® Business – continued

The following table sets forth the condensed operating results of our discontinued operations for the three and six months ended June 30, 2017 and 2016, respectively, (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2017			2016		2017		2016
Net sales	$	(371	)	$	1,826	$	4,687	$	6,179
Cost of sales		264			728		2,037		2,427
Sales and marketing		200			533		1,720		2,833
Administration		-			319		348		656
Research and development		-			48		52		95
Income (loss) from discontinued operations	$	(835	)	$	198	$	530	$	168

Note 4 – Secured Promissory Notes and Other Obligations

Secured Promissory Notes

On December 11, 2015, we executed two Subscription Agreements (the “Subscription Agreements”) with the investors named therein (the “Investors”) providing for the purchase of 12% Secured Promissory Notes – Series A (“Notes”) in the aggregate principal amount of up to $3.0 million and warrants to purchase shares of our Common Stock (the “Warrants”).

Notes in the amount of $1.5 million and 51,000 Warrants, at an exercise price of $1.35 per share, which was equal to the closing price of our Common Stock on the date of investment, were issued by the Company and its wholly-owned subsidiaries, PMI and Quigley Pharma, Inc. (collectively, the “Obligors”), and funded on December 11, 2015. We incurred loan origination costs of $22,000 which were recorded as a reduction of the Notes and the origination costs are charged to other income (expense) over the term of the loan. The Warrants had an exercise term equal to three years and were exercisable commencing on the date of issuance. The fair value of the Warrants at the date of grant was $14,000 which is recorded as a reduction of the Notes and is charged to other income (expense) over the term of the loan.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

The Notes bore interest at the rate of 12% per annum, payable semi-annually and the principal is due and payable on June 15, 2017. The Notes could be pre-paid at any time prior to maturity without penalty. The effective interest, inclusive of the Warrant and loan origination costs, was 14.3% per annum. For the six months ended June 30, 2017 and 2016, we charged to other income (expense) $54,000 and $105,000, respectively, in connection with the Notes.

On March 29, 2017, in connection with the sale of the Cold-EEZE^® Business, we paid in full the remaining principal and accrued interest, in the total amount of $1,553,000, due under the Notes. Of the $1,553,000 paid to the Investors, $69,000 was netted against the aggregate exercise price of the Warrants, which were simultaneously being exercised by the Investors.

In connection with the issuance of the Notes, the Company entered into a security agreement with John E. Ligums, Jr., as collateral agent for the Investors (the “Security Agreement”) to secure the timely payment and performance in full of the Company’s obligations under the Notes. Under the Security Agreement, we granted to the collateral agent, for the benefit of the Investors a lien upon and security interest in the property and assets listed as collateral in the Security Agreement, including without limitation, all of our personal property, inventory, equipment, general intangibles, cash and cash equivalents, and proceeds. In connection with the payoff of the Notes, the Security Agreement was terminated.

Note 5 – Transactions Affecting Stockholders’ Equity

Our authorized capital stock consists of 50 million shares of Common Stock and 1 million shares of preferred stock, $.0005 par value (“Preferred Stock”).

Preferred Stock

On June 16, 2015, our stockholders approved the change to our state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion (the “Conversion Plan”) and the filing of a certificate of incorporation in the State of Delaware. The Preferred Stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of June 30, 2017, no shares of Preferred Stock have been issued. Our board of directors has the full authority permitted by law to establish, without further stockholder approval, one or more series of Preferred Stock and the number of shares constituting each such series and to fix by resolution, voting powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any. Subject to the limitation on the total number of shares of Preferred Stock that we have authority to issue under our certificate of incorporation, the board of directors is also authorized to increase or decrease the number of shares of any series, subsequent to the issue of that series, but not below the number of shares of such series then-outstanding. In case the number of shares of any series is so decreased, the shares constituting such decrease will resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. We may amend from time to time our certificate of incorporation and bylaws to increase the number of authorized shares of Preferred Stock or Common Stock or to make other changes or additions to our capital structure or the terms of our capital stock.

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to our stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009, (iii) June 18, 2014 and (iv) January 6, 2017. The Rights Agreement, as amended and restated, provides that each Right entitles the stockholder of record to purchase from the Company that number of shares of Common Stock having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of Common Stock, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding shares of Common Stock (such person, the “acquirer”). The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

The dividend has the effect of diluting the acquirer by giving our other stockholders a 50% discount on our Common Stock’s current market value for exercising the Rights. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one share of Common Stock of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.

Equity Line of Credit

On July 30, 2015, we entered into a new equity line of credit agreement (such arrangement, the “2015 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”). Pursuant to the 2015 Equity Line, Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,200,000 shares of our Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the Investment Agreement.

We may, at our discretion, draw on the 2015 Equity Line from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2015 Equity Line. The maximum number of shares that we are entitled to put to Dutchess in any one draw down notice shall not exceed 500,000 shares with a purchase price calculated in accordance with the terms of the 2015 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

Note 5 – Transactions Affecting Stockholders’ Equity – continued

The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, we are entitled to deliver another draw down notice. In addition, Dutchess will not be obligated to purchase shares if Dutchess’ total number of shares beneficially held at that time would exceed 4.99% of the number of shares of Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

Pursuant to the terms of the 2015 Equity Line, we are obligated to file one or more registration statements with the SEC to register the resale by Dutchess of the shares of Common Stock issued or issuable under the 2015 Equity Line. In addition, we are obligated to use all commercially reasonable efforts to have the registration statement declared effective by the SEC within 90 days after the registration statement is filed. On August 4, 2015, we filed a registration statement for the underlying shares of the 2015 Equity Line with the SEC and the registration statement was declared effective by the SEC on August 21, 2015.

At June 30, 2017, we have 2,450,000 shares of our Common Stock available for sale, at our discretion, under the terms of our 2015 Equity Line and covered pursuant to an effective registration statement.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

The 2010 Equity Compensation Plan

On May 5, 2010, our stockholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by our stockholders on April 24, 2011, and further amended and approved by stockholders on May 6, 2013, and further amended and approved by stockholders on May 24, 2016 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 3.2 million shares, including 900,000 shares that are authorized for issuance but unissued under a 1997 incentive stock option plan and 700,000 shares added to the 2010 Plan effective May 24, 2016.

For the six month ended June 30, 2017 and 2016, we granted, 600,000 options, exercisable at $2.00 per share and subject to vesting over a four year term, and zero options, respectively, to employees to acquire our Common Stock pursuant to the terms of 2010 Plan. The assumptions used in determining the fair value of the 600,000 stock options granted in Fiscal 2017 were (i) expected option life of 4.5 years, (ii) weighted average risk rate of 1.81%, (iii) dividend yield of 0% and (iv) expected volatility of 44.51%.

For the six months ended June 30, 2017, 90,000 stock options were exercised pursuant to the 2010 Plan and we derived net proceeds of $102,000. For the six months ended June 30, 2016, there were no stock options exercised. At June 30, 2017, there were 2,209,000 options outstanding under the 2010 Plan and 133,659 options available to be issued pursuant to the terms of the 2010 Plan.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our stockholders approved the 2010 Directors’ Equity Compensation Plan, which was subsequently amended and approved by stockholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the six months ended June 30, 2017 and 2016, no shares were granted to our directors. At June 30, 2017, there were 147,808 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

Note 5 – Transactions Affecting Stockholders’ Equity – continued

Treasury Stock Purchase Agreement

On June 12, 2017 we entered into a Stock Purchase Agreement with each of Mark S. Leventhal, a former director of the Company, and certain other persons and entities associated and/or affiliated with Mr. Leventhal (the “Leventhal Holders”), pursuant to which we purchased all 1,061,980 shares of our Common Stock then held by the Leventhal Holders, representing an approximate 6.2% aggregate ownership interest (based on 17,221,776 shares of common stock outstanding as of June 12, 2017). Upon consummation of the transactions, the Leventhal Holders ceased to hold any direct or indirect ownership interest in the Company.

Pursuant to the terms of the Stock Purchase Agreements, the total consideration paid by us to the Leventhal Holders for their shares was $1,858,465, which amount was equal to the product of (i) $1.75 multiplied by (ii) the number of shares purchased.

Note 6 – Income Taxes

At December 31, 2016, there were $47.1 million in net operating loss carryforwards, subject to applicable limitations, available to us for federal purposes which will expire beginning for the year ended December 31, 2020 through 2036. Additionally, there were $22.1 million in net operating loss carryforwards, subject to limitations, available to us for state purposes which will expire beginning for the year ended December 31, 2020 through 2036.

Based upon preliminary estimates, we believe that a significant portion of our income tax liability of $19.5 million arising from our taxable gain for federal and state income tax purposes from the sale of the Cold-EEZE^® Business will be offset to the extent of our current year losses from operations, the write-off for tax purposes of the tax-basis of the Cold-EEZE^®Business and the available net operating loss carryforwards at the federal and state levels. However, for state income tax purposes, based upon the available state net operating loss carryforwards and corresponding limitations, we estimate a net income tax expense arising from the sale of the Cold-EEZE^® Business of $1.3 million.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Utilization of net operating loss carryforwards may be subject to limitations as set forth in Section 382 of the Internal Revenue Code (“Section 382”). Based on our preliminary Section 382 analysis, we do not believe that our current net operating loss carryforwards are subject to these limitations as of June 30, 2017. However, until we complete a final Section 382 analysis upon filing of our 2017 income tax return, there can be no assurances that our preliminary analysis is accurate or complete. Should we identify any limitations upon the completion of our final Section 382 analysis, the impact could be material to our consolidated financial statements and that we could incur additional income tax expense arising from the sale of the Cold-EEZE^® Business.

For the six months ended June 30, 2017, we charged to discontinued operations $19.5 million for estimated federal and state income taxes arising from the sale of the Cold-EEZE^® Business and we have realized an income tax benefit from continuing operations of $18.1 million as a consequence of the utilization of the federal and state net operating losses.

Subsequent to the income tax effects arising from the sale of the Cold-EEZE^® Business, we will continue to have net operating loss carry-forwards for federal income tax purposes. Until sufficient taxable income to offset the temporary timing differences attributable to operations, and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided. As a consequence of the accumulated losses of the Company, we believe that this allowance is required due to the uncertainty of realizing these tax benefits in the future.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 7– Commitments and Contingencies

Escrow Receivable

We have indemnification obligations to Mylan under the Asset Purchase Agreement that may require us to make future payments to Mylan and other related persons for any damages incurred by Mylan or such related persons as a result of any breaches of our representations, warranties, covenants or agreements contained in the Asset Purchase Agreement, or arising from the Retained Liabilities (as such term is defined in the Asset Purchase Agreement) or certain third party claims specified in the Asset Purchase Agreement. Generally, our representations and warranties survive for a period of 24 months from the closing date, other than certain fundamental representations which survive until the expiration of the applicable statute of limitations. There is a limited indemnification cap with respect to a majority of the Company’s indemnification obligations under the Asset Purchase Agreement with the exception of claims for actual fraud, the breach of any fundamental representations and certain other items, which have a larger indemnification cap (e.g., the purchase price).

Pursuant to the terms of the Asset Purchase Agreement, we, Mylan, and an escrow agent entered into an Escrow Agreement at closing, pursuant to which Mylan deposited $5 million of the aggregate purchase price for the Cold-EEZE^® Business into an escrow account established with the Escrow Agent in order to satisfy, in whole or in part, certain of our indemnity obligations under the Asset Purchase Agreement. If, on the 18^thmonth anniversary of the closing date, there are funds remaining in the escrow account, then the escrow account will be reduced by the difference, if a positive number, of (i) $2.5 million minus (ii) the aggregate amount of all escrow claims asserted by Mylan prior to this date that have either been paid out of the escrow account or are pending as of such date, and, within two business days of such date, the Escrow Agent will disburse such difference, if a positive number, to us. Within two business days of the second anniversary of the closing date, the Escrow Agent will release any funds remaining in the escrow account to us minus any amounts being reserved for escrow claims asserted by Mylan prior to such date. Upon the resolution of any pending escrow claims, the Escrow Agent will, within two business days of receipt of joint instructions or a final order from a court (as described in the Escrow Agreement) disburse such reserved amount to the parties entitled to such funds.

Management does not believe that we will be subject to indemnity claims contemplated by the Asset Purchase Agreement. However, in the event that such a claim is made, and if successful, we would be required to pay Mylan pursuant to the indemnification provisions of the Asset Purchase Agreement which may reduce the amount we ultimately collect from escrow or could even require us to return a portion of the net proceeds received from the sale of the Cold-EEZE^® Division.

Manufacturing Agreement

In connection with the Asset Purchase Agreement, the Company and its wholly-owned subsidiary, PMI, entered into a Manufacturing Agreement (the “Manufacturing Agreement”) with Mylan. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) will purchase the inventory of the Company’s Cold-EEZE^® brand and product line and PMI will manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2022. Thereafter, the Manufacturing Agreement may be renewed by Mylan for up to five successive one year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.

Transition Services Agreement

In connection with the Asset Purchase Agreement, we entered into a transition services agreement with Mylan to provide litigation support, insurance coverage, supply chain, customer support, finance, accounting, commercial advertising and packaging services, quality control, IT and research and development services to Mylan for time periods ranging from two to nine months from the closing date. We will continue to incur certain operating costs during the transition period to support Mylan.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 7– Commitments and Contingencies – continued

Future Obligations:

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2017, as follows (in thousands):

Fiscal year	Employment Contracts
2017		338
2018		675
2019		-
2020		-
2021		-
Total	$	1,013

Note 8 – Earnings (Loss) Per Share

Basic earnings (loss) per share for continuing and discontinued operations are computed by dividing respective net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at June 30, 2017 and 2016 were 2,209,000 and 1,706,500, respectively.

For the three months ended June 30, 2017 and June 30, 2016 dilutive earnings (loss) per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended June 30, 2017 and 2016 there were 641,754 and 276,165, Common Stock Equivalents which were in the money, that were excluded from the earnings (loss) per share computation as a consequence of their anti-dilutive effect.

For the six months ended June 30, 2017 there were 650,190 Common Stock Equivalents which were in the money, that were included in the fully diluted earnings per share computation. For the six months ended June 30, 2016, for continuing operations dilutive earnings (loss) per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the six months ended June 30, 2016, there were 244,112, Common Stock Equivalents which were in the money, that were excluded from the earnings (loss) per share computation as a consequence of their anti-dilutive effect.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our interim unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q (“Quarterly Report”) and the audited financial statements and notes thereto as of and for the year ended December 31, 2016 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2017 (the “2016 Annual Report”). As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “ProPhase” refer to ProPhase Labs, Inc. and its subsidiaries and consolidated variable interest entities, unless the context otherwise requires.

General

ProPhase was initially organized in Nevada in July 1989. Effective June 18, 2015, we changed our state of incorporation from the State of Nevada to the State of Delaware. We are a manufacturer, marketer and distributor of a diversified range of health care products and cold remedy products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug and natural base health products including supplements, personal care and cosmeceutical products.

Discontinued Operations

Prior to March 29, 2017, our flagship OTC drug brand was Cold-EEZE^® and our principal product was Cold-EEZE^®cold remedy zinc gluconate lozenges and various non-lozenge forms of our proprietary zinc gluconate formulation. On January 6, 2017, we signed an asset purchase agreement (as amended, the “Asset Purchase Agreement”), by and among the Company, Meda Consumer Healthcare Inc. (“MCH”) and Mylan Inc. (together with MCH, “Mylan”), for the sale of assets by us to Mylan. The sale of assets (i) was subject to stockholder approval and other customary closing conditions and (ii) consisted principally of the sale of our intellectual property rights and other assets relating to our Cold-EEZE^® brand and product line (collectively, referred to herein as the “Cold-EEZE^® Business”) to Mylan, including all current and pipeline over-the-counter allergy, cold, flu, multi-symptom relief and immune support treatments for adults and children to the extent each is, or is intended to be, branded “Cold-EEZE^®”, and all private label versions thereof, including all formulations and derivatives thereof as set forth in the Asset Purchase Agreement.

A special meeting of our stockholders was held on March 29, 2017 (the “Special Meeting”). At the Special Meeting, our stockholders approved the sale of assets and the transactions contemplated by the Asset Purchase Agreement. Effective March 29, 2017, we completed the sale of the Cold-EEZE^®Business to Mylan. As a consequence of the sale of the Cold-EEZE^®Business, for the three and six months ended June 30, 2017 and 2016, we have classified as discontinued operations (i) the gain from the sale of the Cold-EEZE^® Business, (ii) all income and expenses attributable to the Cold-EEZE^®Business and (iii) the income tax expense attributed to the sale of the Cold-EEZE^® Business. Excluded from the sale of the Cold-EEZE^®Business were our accounts receivable and inventory, and we also retained all liabilities associated with our Cold-EEZE^®Business operations arising prior to March 29, 2017.

Continuing Operations and Product Development

We continue to own and operate our manufacturing facility and manufacturing business in Lebanon, Pennsylvania, and our headquarters in Doylestown, Pennsylvania. As part of the sale of the Cold-EEZE^® Business, we entered into a manufacturing agreement with Mylan and our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), to supply various Cold-EEZE^®lozenge products to Mylan. In addition to the production service we provide to Mylan under the manufacturing agreement, we produce OTC drug and dietary supplement lozenges and other products for other third party customers in addition to performing operational tasks such as warehousing, customer order processing and shipping. We will seek to expand our contract manufacturing operations through developing new products and creating new contract manufacturing opportunities.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

We are also pursuing a series of new product development and pre-commercialization initiatives in the dietary supplement category. Initial dietary supplement product development activities were completed in the fourth quarter of Fiscal 2015 under the brand name of TK Supplements^®. The TK Supplements^® product line comprises three men’s health products: (i) Legendz XL^® for sexual health, (ii) Triple Edge XL^®, a daily energy booster plus testosterone support, and (iii) Super ProstaFlow Plus^TM for prostate and urinary health. We recently completed a broad series of clinical studies which support important product claims which have now been incorporated in our product packaging and marketing communication. In addition to developing direct-to-consumer (“Direct Response”) marketing strategies of Legendz XL^®, we received initial product acceptance and shipped into a national chain drug retailer during the second quarter of Fiscal 2017. In addition, we have received initial product acceptance from several regional retailers to begin shipments in the third and fourth quarters of Fiscal 2017.

If we are successful in achieving retail distribution, we intend to ramp up the media spend for our Direct Response TV spots to support this retail launch with the added benefit that it should also generate additional direct to consumer sales. As with any new product launch, we anticipate losses from our TK Supplements^® initiatives as we optimize our retail and direct response strategy. Therefore, no assurance can be made that our new product efforts will be successful and/or profitable.

Additionally, we are active in exploring new product technologies, applications, product line extensions, new contract manufacturing applications and other new product opportunities consistent with our Company and brand image, and our standard of proven consumer benefit and efficacy.

Seasonality of the Business

Our net sales are derived principally from our OTC heath care and cold remedy products sold in the United States of America. Our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net sales. Revenues and related marketing costs are generally at their lowest levels in the second quarter when customer demand generally declines.

Financial Condition and Results of Operations

Results from Continuing Operations for the Three Months Ended June 30, 2017

as Compared to the Three Months Ended June 30, 2016

For the three months ended June 30, 2017, net sales were $1.9 million as compared to $1.0 million for the three months ended June 30, 2016. The increase in net sales from period to period is due principally to an increase in the timing of shipments of lozenge-based products principally as a result of initial shipments to Mylan’s new OTC warehouse facility.

Cost of sales for the three months ended June 30, 2017 were $1.8 million as compared to $993,000 for the three months ended June 30, 2016. Gross margins are generally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the three months ended June 30, 2017 was $221,000 as compared to $236,000 for the three months ended June 30, 2016. The decrease of $15,000 in sales and marketing expense for the three months ended June 30, 2017 as compared to the three months ended June 30, 2016 was principally due to a decrease in personnel and other sales costs.

General and administration (“G&A”) expenses for the three months ended June 30, 2017 was $1.3 million as compared to $943,000 for the three months ended June 30, 2016. The increase of $363,000 in G&A expense for the three months ended June 30, 2017 as compared to the three months ended June 30, 2016 was principally due to increases to professional services and personnel.

Research and development costs during the three months ended June 30, 2017 was $224,000, as compared to $121,000 for the three months ended June 30, 2016. The increase in research and development costs for the three months ended June 30, 2017 as compared to the three months ended June 30, 2016 was due principally to an increase in the amount and timing of our product development expenditures.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Other income (expense) for the three months ended June, 2017 and 2016 was income of $151,000 compared to an expense of $53,000, respectively. The income for the three month ended June 30, 2017 was principally the result of the $150,000 of transition service fees earned by us. Other expense for the three months ended June 30, 2016 was principally comprise of the interest expense, inclusive of the warrant and loan origination costs, incurred pursuant to the terms of the secured promissory notes which were repaid on March 29, 2017.

For the three months ended June 30, 2017 and 2016, results from operations for our Cold-EEZE^® Business are classified as discontinued operations. The carve out of the discontinued operations are derived from identifying and carving out the specific assets, liabilities, net sales, cost of sales, operating expenses and interest expense associated with the Cold-EEZE^®Business’s operations. In addition, G&A, including personnel expenses, and bonuses, and research and development overhead costs incurred by us (for which the discontinued operation benefits from such resources) are allocated to discontinued operations based upon the percentage of the Cold-EEZE^® Business’s net sales to our consolidated net sales. For the three months ended June 30, 2017 and 2016, we allocated (i) zero and $319,000, respectively, included in G&A and (ii) zero and $48,000, respectively, included in research and development expenses, in the accompanying condensed statements of operations.

As a consequence of the effects of the above, the net loss from continuing operations for the three months ended June 30, 2017 was $1.5 million, or ($0.09) per share, as compared to a net loss of $1.3 million, or ($0.08) per share, for the three months ended June 30, 2016. Net loss from discontinued operations for the three months ended June 30, 2017 was $845,000, or ($0.05) per share, as compared to net income of $198,000, or $0.01 per share, for the three months ended June 30, 2016. Net loss for the three months ended June 30, 2017 was $2.3 million, or ($0.14) per share, as compared to a net loss of $1.1 million, or ($0.07) per share, for the three months ended June 30, 2016.

Financial Condition and Results of Operations

Results from Continuing Operations for the Six Months Ended June 30, 2017

as Compared to the Six Months Ended June 30, 2016

For the six months ended June 30, 2017, net sales were $2.7 million as compared to $2.0 million for the six months ended June 30, 2016. The increase in net sales from period to period is due principally to an increase in the timing of shipments of lozenge-based products principally as a result of initial shipments to Mylan’s new OTC warehouse facility.

Cost of sales for the six months ended June 30, 2017 were $2.4 million as compared to $1.7 million for the six months ended June 30, 2016. Gross margins are generally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, and the timing of shipments to customers, which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the six months ended June 30, 2017 was $336,000 as compared to $534,000 for the six months ended June 30, 2016. The decrease of $198,000 in sales and marketing expense for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016 was principally due to a decrease in advertising costs.

General and administration (“G&A”) expenses for the six months ended June 30, 2017 was $2.4 million as compared to $2.1 million for the six months ended June 30, 2016. The increase of $241,000 in G&A expense for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016 was principally due to the net effect of (i) an increase principally due to a one-time charge for certain obsolete equipment, offset by (ii) a decrease in professional and legal fees.

Research and development costs during the six months ended June 30, 2017 was $258,000 as compared to $160,000 for the six months ended June 30, 2016. The increase in research and development costs for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016 was due principally to an increase in the amount and timing of our product development expenditures.

Other income (expense) for the six months ended June 30, 2017 and 2016 was income of $97,000 compared to an expense of $105,000, respectively. Other income (expense) for the six month ended June 30, 2017 was principally the result of the net effects of (i) $150,000 of transition service fees earned by us, offset by (ii) interest expense, inclusive of the warrant and loan origination costs, of $54,000 incurred pursuant to the terms of the secured promissory notes. Other income (expense) for the six months ended June 30, 2016 was principally comprise of the interest expense, inclusive of the warrant and loan origination costs, incurred pursuant to the terms of the secured promissory notes which were repaid on March 29, 2017.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

For the six months ended June 30, 2017 and 2016, results from operations for our Cold-EEZE^® Business are classified as discontinued operations The carve out of the discontinued operations are derived from identifying and carving out the specific assets, liabilities, net sales, cost of sales, operating expenses and interest expense associated with the Cold-EEZE^®Business’s operations. In addition, G&A, including personnel expenses and bonuses, and research and development overhead expenses incurred by us (for which the discontinued operation benefits from such resources) are allocated to discontinued operations based upon the percentage of the Cold-EEZE^® Business’s net sales to our consolidated net sales. For the six months ended June 30, 2017 and 2016, we allocated (i) $348,000 and $656,000, respectively, included in G&A and (ii) $52,000 and $95,000, respectively, included in research and development expenses, in the accompanying statements of operations.

As a consequence of the sale of the Cold-EEZE^® Business, we recorded a gain on the sale of the assets of $26.3 million, net of $19.5 million of income tax.

As a consequence of the effects of the above, the net income from continuing operations for the six months ended June 30, 2017 was $15.5 million, or $0.91 per share, as compared to a net loss of $2.6 million, or ($0.15) per share, for the six months ended June 30, 2016. Net income from discontinued operations for the six months ended June 30, 2017 was $26.9 million, or $1.58 per share, as compared to net income of $168,000, or $0.01 per share, for the six months ended June 30, 2016. Net income for the six months ended June 30, 2017 was $42.3 million, or $2.49 per share, as compared to a net loss of $2.5 million, or ($0.14) per share, for the six months ended June 30, 2016.

Liquidity and Capital Resources

Our aggregate cash and cash equivalents as of June 30, 2017 were $37.3 million compared to $441,000 at December 31, 2016. The increase of $36.9 million in our cash balance for the six months ended June 30, 2017 was principally due to the net effect of (i) the net proceeds of $40.8 million, excluding the $5.0 million escrow receivable, derived from the sale of the Cold-EEZE^® Business, (ii) proceeds from the exercise of stock options and warrants of $171,000, offset by (iii) payments of $1.5 million to retire the secured promissory notes, (iv) payments of $1.9 for the repurchase our Common Stock and (v) capital expenditures of $132,000.

Equity Line of Credit

We may, at our discretion, draw on the 2015 Equity Line from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2015 Equity Line. The maximum number of shares that we are entitled to put to Dutchess in any one draw down notice shall not exceed 500,000 shares with a purchase price calculated in accordance with the 2015 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. In addition, Dutchess will not be obligated to purchase shares if Dutchess’ total number of shares beneficially held at that time would exceed 4.99% of the number of shares of Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

Pursuant to the terms of the 2015 Equity Line, we are obligated to file one or more registrations statements with the SEC to register the resale by Dutchess of the shares of Common Stock issued or issuable under the 2015 Equity Line. In addition, we are obligated to use all commercially reasonable efforts to have the registration statement declared effective by the SEC within 90 days after the registration statement is filed. On August 4, 2015, we filed a registration statement for the underlying shares of the 2015 Equity Line with the SEC and the registration statement was declared effective by the SEC on August 21, 2015.

At June 30, 2017, we have 2,450,000 shares of our Common Stock available for sale, at our discretion, under the terms of the 2015 Equity Line and covered pursuant to an effective registration statement.

General

As a consequence of the seasonality of our business, we realize variations in operating results and demand for working capital from quarter to quarter. As of June 30, 2017, we had working capital of approximately $38.8 million and 2,450,000 shares of Common Stock available for sale under the 2015 Equity line. We believe our current working capital, cash generated from operations and available 2015 Equity Line is an acceptable and adequate level of working capital to support our business for at least the next twelve months.

Our current cash position supports our (i) operations, (ii) reorganization costs associated with the sale of the Cold-EEZE^®Business, (iii) current research and development expenditures and (iv) initial operating losses related to new products, including the launch of Legendz XL^®. Additionally, we are active in exploring new product technologies, applications, product line extensions, new contract manufacturing applications and other new business opportunities consistent with our Company and brand image, and our standard of proven consumer benefit and efficacy.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Management is not aware of any other trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net sales or income from continuing operations. Any challenge to our patent or trademark rights could have a material adverse effect on our future; however, we are not aware of any condition that would make such an event probable. Our business is subject to seasonal variations thereby impacting our liquidity and working capital during the course of our fiscal year.

To the extent that we do not generate sufficient cash from operations, our cash balances will decline. We may also use our cash to explore and/or acquire new product technologies, applications, product line extensions, new contract manufacturing applications and other new business opportunities. In the event that our available cash is insufficient to support such initiatives, we may need to incur indebtedness or issue Common Stock to finance plans for growth. Volatility in the credit markets and the liquidity of major financial institutions may have an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly created instruments in the public or private markets on terms that we believe to be reasonable, if at all.

Off-Balance Sheet Arrangements

It is not our usual business practice to enter into off-balance sheet arrangements such as guarantees on loans and financial commitments and retained interests in assets transferred to an unconsolidated entity for securitization purposes. We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Our significant accounting policies are described in Note 2 of Notes to Condensed Consolidated Financial Statements included under Item 1 of this Part I. However, certain accounting policies are deemed “critical”, as they require management’s highest degree of judgment, estimates and assumptions. These accounting estimates and disclosures have been discussed with Audit Committee of our Board of Directors. A discussion of our critical accounting policies, the judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions are as follows:

Revenue Recognition – Sales Allowances

When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Income Taxes

As of December 31, 2016, we have net operating loss carry-forwards of approximately $47.1 million for federal purposes that will expire beginning in Fiscal 2020 through 2036. Additionally, there are net operating loss carry-forwards of $22.1 million for state purposes that will expire beginning in Fiscal 2020 through 2036.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Until sufficient taxable income to offset the temporary timing differences attributable to operations, and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided. As a consequence of the accumulated losses of the Company, we believe that this allowance is required due to the uncertainty of realizing these tax benefits in the future.

Recently Issued Accounting Standards

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward looking statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict. Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Quarterly Report may contain forward-looking statements attributed to third parties relating to their estimates regarding the growth of our markets. You are cautioned that such forward looking statements are not guarantees of future performance and that all forward-looking statements address matters that involve risk and uncertainties, and there are many important risks, uncertainties and other factors that could cause our actual results, levels of activity, performance, achievements and prospects, as well as those of the markets we serve, to differ materially from the forward-looking statements contained in this Quarterly Report.

Such risks and uncertainties include, but are not limited to:

●	The ability of our management to successfully implement our business plan and strategy;
●	Our ability to fund our operations including the cost and availability of capital and credit;
●	Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;
●	Our ability to grow our manufacturing business and operate it profitably;
●	Our ability to successfully develop and commercialize our existing products and new products without leveraging the Cold-EEZE^®brand name;
●	Changes in our retail and distribution customers strategic business plans including, but not limited to, (i) expansions, mergers, and/or consolidations, (ii) retail shelf space allocations for products within each outlet and in particular the homeopathic and health care category in which we compete, (iii) changes in their private label assortment and (iv) product selections, distribution allocation, merchandising programs and retail pricing of our products as well as competitive products;
●	The general financial and economic uncertainty, fluctuations in consumer confidence and the strength of the United States economy, and their impacts on our business including demand for our products;
●	Our ability to protect our proprietary rights;
●	Our continued ability to comply with regulations relating to our current products and any new products we develop, including our ability to effectively respond to changes in laws and regulations or the interpretation thereof including changing market rules and evolving federal, state and regional laws and regulations;
●	Potential disruptions in our ability to manufacture our products or our access to raw materials;
●	Seasonal fluctuations in demand for our products;
●	Our ability to attract, retain and motivate our key employees;
●	Other risks identified in this Quarterly Report.

You should also consider carefully the statements under other sections of this Quarterly Report and our 2016 Annual Report, as well as in other documents we file from time to time with the SEC which address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Like virtually all commercial enterprises, we can be exposed to the risk (“market risk”) that the cash flows to be received or paid relating to certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices and other market changes.

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including due to a reduction in the availability of credit, financial market volatility and recession.

Item 4. Controls and Procedures.

The management of the Company, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2017. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of that date, the Company’s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended June 30, 2017, there were no changes in our internal control over financial reporting that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurances that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. However, our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives.

Part II. Other Information

Item 1. Legal Proceedings.

The Company is not currently involved in any legal proceeding arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters.

Item 1A. Risk Factors.

The risks described in Item 1A. Risk Factors of our Quarterly Report on Form 10-Q filed with the SEC on May 15, 2017 (“May 2017 Quarterly Report”) are updated as follows:

Any of the following risks could materially affect our business, financial condition, or results of operations. These risks could also cause our actual results to differ materially from those indicated in the forward-looking statements contained herein and elsewhere. The risks described in our May 2017 Quarterly Report, as updated below are not the only risks facing us. Additional risks not currently known to us or those we currently deem to be immaterial may also materially and adversely affect our business, financial condition or results of operations.

We have a history of losses

We have experienced net losses for each of the four of the past five fiscal years. There can be no assurance that our strategic focus will result in any revenue growth or that we will be successful in initiating or acquiring any new lines of business, or that any such new lines of business will achieve profitability. As of June 30, 2017, we had working capital of approximately $38.8 million which we believe is an acceptable and adequate level of working capital to support our business for at least the next twelve months ending August 2018. Our ability to fund working capital and debt service needs will depend on our ability to generate cash in the future.

Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations

In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the “Section 382”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change net operating loss carryforwards, or NOLs, to offset future taxable income. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382. Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to limitations.

Based on our preliminary Section 382 analysis, we do not believe that our current net operating loss carryforwards are subject to these limitations as of June 30, 2017. However, until we complete a final Section 382 analysis upon filing of our 2017 income tax return, there can be no assurances that our preliminary analysis is accurate or complete. Should we identify any limitations upon the completion of our final Section 382 analysis, the impact could be material to our consolidated financial statements and that we could incur additional income tax expense arising from the sale of the Cold-EEZE^® Business.

Future sales of shares of our Common Stock in the public market could adversely affect the trading price of shares of our Common Stock and our ability to raise funds in new stock offerings

Future sales of substantial amounts of shares of our Common Stock in the public market, or the perception that such sales are likely to occur, could affect prevailing trading prices of our Common Stock.

As of June 30, 2017, there were outstanding options, which were fully vested, to purchase an aggregate of 1,609,000 shares of our Common Stock at an average exercise price of $1.21 per share. If these options are exercised, and the holders of these options were to attempt to sell a substantial amount of their holdings at once, the market price of our Common Stock would likely decline. Moreover, the perceived risk of this potential dilution could cause stockholders to attempt to sell their shares and investors to “short” our stock, a practice in which an investor sells shares that he or she does not own at prevailing market prices, hoping to purchase shares later at a lower price to cover the sale. As each of these events would cause the number of shares of Common Stock being offered for sale to increase, our Common Stock’s market price would likely further decline. All of these events could combine to make it very difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.

Our officers and directors own a substantial amount of our Common Stock

As of June 30, 2017, our executive officers and directors beneficially owned approximately 25% of our Common Stock. These individuals have significant influence over the outcome of all matters submitted to stockholders for approval, including the election of directors. Consequently, they exercise substantial influence over all major decisions including major corporate actions such as mergers and other business combinations transactions which could result in or prevent a change of control of the Company. Circumstances may occur in which the interests of our officers and directors could be in conflict with the interests of other stockholders. Accordingly, a stockholder’s ability to influence us through voting their shares may be limited or the market price of our Common Stock may be adversely affected.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

None

Item 6. Exhibits

Exhibit No.		Description

10.1		Stock Purchase Agreement, dated June 12, 2017, by and between ProPhase Labs, Inc. and Mark Leventhal (incorporated by reference to Exhibit 10.1 to the Form 8-K (File No. 000-21617) filed on June 14, 2017

10.2		Stock Purchase Agreement, dated June 12, 2017, by and between ProPhase Labs, Inc. and Mark S. Leventhal and Donna R. Leventhal (incorporated by reference to Exhibit 10.2 to the Form 8-K (File No. 000-21617) filed on June 14, 2017

10.3		Stock Purchase Agreement, dated June 12, 2017, by and between ProPhase Labs, Inc. and Mark S. and Donna R Family Foundation, Inc. (incorporated by reference to Exhibit 10.3 to the Form 8-K (File No. 000-21617) filed on June 14, 2017

10.4		Stock Purchase Agreement, dated June 12, 2017, by and between The Bonnybrook Trust and ProPhase Labs, Inc. (incorporated by reference to Exhibit 10.4 to the Form 8-K (File No. 000-21617) filed on June 14, 2017

31.1		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101. INS#		XBRL Instance Document

101.SCH#		XBRL Taxonomy Extension Schema Document

101.CAL#		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF#		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB#		XBRL Taxonomy Extension Label Linkbase Document

101.PRE#		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ProPhase Labs, Inc.

	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

Date: August 11, 2017

	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Financial Officer
		(Principal Accounting and Financial Officer)

Date: August 11, 2017

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Ted Karkus, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

2.	Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;

3.	Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2017

	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert V. Cuddihy, Jr., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

2.	Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;

3.	Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2017

	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
	(Principal Executive Officer)
	August 11, 2017

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert V. Cuddihy, Jr., Chief Financial Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Robert V. Cuddihy, Jr.
	Robert V. Cuddihy, Jr.
	Chief Financial Officer
	(Principal Accounting and Financial Officer)
	August 11, 2017

EX-101.INS 6 prph-20170630.xml XBRL INSTANCE FILE 0000868278 2017-01-01 2017-06-30 0000868278 2016-12-31 0000868278 2017-06-30 0000868278 PRPH:EstimatedFutureSalesReturnMember 2017-06-30 0000868278 us-gaap:EmploymentContractsMember 2017-06-30 0000868278 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000868278 us-gaap:StateAndLocalJurisdictionMember 2016-01-01 2016-12-31 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2010-05-05 0000868278 PRPH:TwoThousandFifteenEquityLineOfCreditMember PRPH:DutchessMember 2015-07-29 2015-07-30 0000868278 us-gaap:SecuredDebtMember 2015-12-11 0000868278 2015-12-11 0000868278 2015-12-10 2015-12-11 0000868278 us-gaap:CommonStockMember 2016-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000868278 us-gaap:RetainedEarningsMember 2016-12-31 0000868278 us-gaap:TreasuryStockMember 2016-12-31 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000868278 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-06-30 0000868278 PRPH:StockholderRightsPlanMember 2017-01-01 2017-06-30 0000868278 PRPH:TwoThousandFifteenEquityLineOfCreditMember PRPH:DutchessMember 2017-01-01 2017-06-30 0000868278 PRPH:TwoThousandFifteenEquityLineOfCreditMember PRPH:DutchessMember 2017-06-30 0000868278 PRPH:TwoThosandTenDirectorsEquityCompensationPlanMember 2017-06-30 0000868278 PRPH:StockholderRightsPlanMember 2017-06-30 0000868278 2016-01-01 2016-06-30 0000868278 PRPH:ChairmanandChiefExecutiveOfficerMember PRPH:RightsAgreementMember 2017-01-01 2017-06-30 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2016-05-24 0000868278 2016-06-30 0000868278 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0000868278 us-gaap:CommonStockMember 2017-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000868278 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0000868278 us-gaap:RetainedEarningsMember 2017-06-30 0000868278 us-gaap:TreasuryStockMember 2017-01-01 2017-06-30 0000868278 us-gaap:TreasuryStockMember 2017-06-30 0000868278 2015-12-31 0000868278 2016-01-01 2016-12-31 0000868278 PRPH:EstimatedFutureSalesReturnMember 2016-12-31 0000868278 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-06-30 0000868278 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-06-30 0000868278 PRPH:ColdEEZEBusinessMember 2017-03-28 2017-03-29 0000868278 PRPH:ColdEEZEBusinessMember PRPH:InvestorsMember 2017-03-28 2017-03-29 0000868278 PRPH:NineteeenNinetySevenEquityCompensationPlanMember 2010-05-05 0000868278 PRPH:TwoThosandTenDirectorsEquityCompensationPlanMember 2017-01-01 2017-06-30 0000868278 PRPH:MylanandEscrowAgentMember PRPH:EscrowAgreementMember 2017-06-30 0000868278 PRPH:MylanandEscrowAgentMember PRPH:EscrowAgreementMember 2017-01-01 2017-06-30 0000868278 PRPH:ColdEEZEBusinessMember 2017-06-30 0000868278 PRPH:ColdEEZEBusinessMember 2017-01-01 2017-06-30 0000868278 PRPH:CooperativeIncentiveMember 2017-01-01 2017-06-30 0000868278 us-gaap:BuildingImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0000868278 us-gaap:BuildingImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0000868278 PRPH:ComputerSoftwareMember 2017-01-01 2017-06-30 0000868278 PRPH:CooperativeIncentiveMember 2016-01-01 2016-12-31 0000868278 PRPH:AssetPurchaseAgreementMember 2017-06-30 0000868278 PRPH:AssetPurchaseAgreementMember 2017-01-01 2017-06-30 0000868278 2017-04-01 2017-06-30 0000868278 2016-04-01 2016-06-30 0000868278 2017-08-11 0000868278 us-gaap:SegmentDiscontinuedOperationsMember 2017-04-01 2017-06-30 0000868278 us-gaap:SegmentDiscontinuedOperationsMember 2016-04-01 2016-06-30 0000868278 PRPH:AssetPurchaseAgreementMember PRPH:MylanMember 2017-01-01 2017-06-30 0000868278 PRPH:AssetPurchaseAgreementMember PRPH:MylanMember 2017-06-30 0000868278 PRPH:AssetPurchaseAgreementMember PRPH:MylanMember 2017-04-01 2017-06-30 0000868278 2017-06-15 0000868278 PRPH:EmployeesMember 2017-01-01 2017-06-30 0000868278 PRPH:EmployeesMember 2016-01-01 2016-06-30 0000868278 PRPH:TwoThousandTenPlanMember 2017-06-30 0000868278 PRPH:StockPurchaseAgreementMember 2017-06-11 2017-06-12 0000868278 PRPH:StockPurchaseAgreementMember 2017-06-12 0000868278 PRPH:StockPurchaseAgreementMember PRPH:LeventhalHoldersMember 2017-06-11 2017-06-12 0000868278 PRPH:StockPurchaseAgreementMember PRPH:LeventhalHoldersMember 2017-06-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2017-06-30 Q2 ProPhase Labs, Inc. --12-31 Smaller Reporting Company PRPH

5134000

5274000

0.0005

50000000

9232817

10294797

2209000

17221776

26313593

26454593

147808

1.35

0.0005

1000000

1404000

1590000

466000

342000

866000

34000

3000000

51000

14000

2017-06-15

0.143

22000

1500000

54000

105000

The components of inventory are as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; text-align: justify; line-height: 107%">Raw materials</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">1,590</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">1,404</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Work in process</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">342</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">466</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">34</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">866</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,966</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,736</td> <td style="line-height: 107%"> </td></tr> </table>

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2017, as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Fiscal year</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Employment Contracts</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; text-align: center; line-height: 107%">2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 26%; text-align: right; line-height: 107%">338</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">675</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 60pt; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,013</td> <td style="line-height: 107%"> </td></tr> </table>

0000868278

5962000

46626000

13000

56378000

-19687000

-30742000

13000

56567000

22646000

-32600000

258000

160000

52000

95000

224000

121000

48000

-18123000

18123000

42333000

-2463000

42333000

-2305000

-1127000

26339000

19500000

-10000

530000 168000 -835000 198000

17080776

16159796

51000

171000

348000

656000

319000

52000 95000 48000

1600000

1700000

400000

934000

1200000

108000

53000

339000

2800000

3300000

598000

1500000

21000

139000

205000

471000

263000

17000

18000

1000

18000

1000

4687000

6179000

-371000

1826000

2037000

2427000

264000

728000

1720000 2833000 200000 533000

0.12

1553000

69000 50000000 -4175000 13000

45812000

19473000 43145000

133659

47100000

22100000 Expire beginning for the year ended December 31, 2020 through 2036 Expire beginning for the year ended December 31, 2020 through 2036

5000000

2022-03-29

650190

244112

641754

276165

19500000 1300000

43000

-43000

P3Y

P7Y

P5Y

P10Y

P39Y

P3Y

P10Y P3Y

Note 1 – Organization and Business   ProPhase Labs, Inc. (“we”, “us” or the “Company”) was initially organized in Nevada in July 1989. Effective June 18, 2015, we changed our state of incorporation from the State of Nevada to the State of Delaware. We are a manufacturer, marketer and distributor of a diversified range of health care and cold remedy products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug and natural base health products including supplements, personal care and cosmeceutical products.   Discontinued Operations   Prior to March 29, 2017, our flagship OTC drug brand was Cold-EEZE® and our principal product was Cold-EEZE® cold remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold. In addition to Cold-EEZE® cold remedy lozenges, we also marketed and distributed non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE® cold remedy QuickMelts®, (ii) Cold-EEZE® Gummies and (iii) Cold-EEZE® cold remedy Oral Spray. Each of the Cold-EEZE® QuickMelts® and Gummies products are based on a proprietary zinc gluconate formulation in combination with certain (i) immune system support, (ii) energy, (iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients.   On January 6, 2017, we signed an asset purchase agreement (as amended, the “Asset Purchase Agreement”), by and among the Company, Meda Consumer Healthcare Inc. (“MCH”) and Mylan Inc. (together with MCH, “Mylan”), for the sale of assets by us to Mylan (see Note 3). The sale of assets (i) was subject to stockholder approval and other customary closing conditions and (ii) consisted principally of the sale of our intellectual property rights and other assets relating to our Cold-EEZE® brand and product line (collectively, referred to herein as the “Cold-EEZE® Business”) to Mylan, including all current and pipeline over-the-counter allergy, cold, flu, multi-symptom relief and immune support treatments for adults and children to the extent each is, or is intended to be, branded “Cold-EEZE®”, and all private label versions thereof, including all formulations and derivatives thereof as set forth in the Asset Purchase Agreement.   A special meeting of our stockholders was held on March 29, 2017 (the “Special Meeting”). At the Special Meeting, our stockholders approved the sale of assets and the transactions contemplated by the Asset Purchase Agreement. Effective March 29, 2017, we completed the sale of the Cold-EEZE® Business to Mylan. As a consequence of the sale of the Cold-EEZE® Business, for the three and six months ended June 30, 2017 and 2016, we have classified as discontinued operations (i) the gain from the sale of the Cold-EEZE® Business, (ii) all income and expenses attributable to the Cold-EEZE® Business and (iii) the income tax expense attributed to the sale of the Cold-EEZE® Business (see Notes 3 and 6). Excluded from the sale of the Cold-EEZE® Business were our accounts receivable and inventory, and we also retained all liabilities associated with our Cold-EEZE® Business operations arising prior to March 29, 2017.   Continuing Operations   We continue to own and operate our manufacturing facility and manufacturing business in Lebanon, Pennsylvania, and our headquarters in Doylestown, Pennsylvania. As part of the sale of the Cold-EEZE® Business, we entered into a manufacturing agreement (see Note 7) with Mylan and our wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), to supply various Cold-EEZE® lozenge products to Mylan. In addition to the production services we provide to Mylan under the manufacturing agreement, we produce OTC drug and dietary supplement lozenges and other products for other third party customers in addition to performing operational tasks such as warehousing, customer order processing and shipping.   We are also pursuing a series of new product development and pre-commercialization initiatives in the OTC dietary supplement category. Initial OTC dietary supplement product development activities were completed in the fourth quarter of Fiscal 2015 under the brand name of TK Supplements®. The TK Supplements® product line comprises three men’s health products: (i) Legendz XL® for sexual health, (ii) Triple Edge XL®, a daily energy booster plus testosterone support, and (iii) Super ProstaFlow PlusTM for prostate and urinary health. We recently completed a broad series of clinical studies which support important product claims which have now been incorporated in our product packaging and marketing communications. In addition to developing direct-to-consumer (“Direct Response”) marketing strategies of Legendz XL®, we received initial product acceptance and shipped into a national chain drug retailer during the second quarter of Fiscal 2017. In addition, we have received initial product acceptance from several regional retailers to begin shipments in the third and fourth quarters of Fiscal 2017.   For the three and six months ended June 30, 2017 and 2016, our revenues from continuing operations have come principally from our OTC health care products.   We use a December 31 year-end for financial reporting purposes. References herein to “Fiscal 2017” shall mean the fiscal year ended December 31, 2017 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies   Basis of Presentation   The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of operating results that may be achieved over the course of the full year. Historical financial statements have been reclassified to conform to the current period presentation, principally reflecting the sale of Cold-EEZE® Business as discontinued operations.   Discontinued Operations Carve Out and ProPhase Allocations   For the three and six months ended June 30, 2017 and 2016, results from operations for our Cold-EEZE® Business are classified as discontinued operations The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, net sales, cost of sales, operating expenses and interest expense associated with the Cold-EEZE® Business’s operations. General administrative and overhead expenses, including personnel expenses and bonuses, and research and development overhead expenses incurred by us (for which the discontinued operation benefits from such resources) are allocated to discontinued operations based upon the percentage of the Cold-EEZE® Business’s net sales to our consolidated net sales. For the three months ended June 30, 2017 and 2016, we allocated (i) zero and $319,000, respectively, of administrative expenses and (ii) zero and $48,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations. For the six months ended June 30, 2017 and 2016, we allocated (i) $348,000 and $656,000, respectively, of administrative expenses and (ii) $52,000 and $95,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations (see Note 3).   Seasonality of the Business   Our net sales are derived principally from our OTC heath care and cold remedy products sold in the United States of America. Our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net sales. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.   For the three and six months ended June 30, 2017 and 2016, our net sales were principally related to domestic markets.   Use of Estimates   The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment, impairment of property and equipment, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.   Cash and Cash Equivalents   We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.   Inventory Valuation   Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2017 and December 31, 2016, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $1.7 million and $1.6 million, respectively. The components of inventory are as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; text-align: justify; line-height: 107%">Raw materials</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">1,590</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">1,404</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Work in process</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">342</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">466</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">34</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">866</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,966</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,736</td> <td style="line-height: 107%"> </td></tr> </table>   Property, Plant and Equipment   Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements – ten to thirty-nine years; machinery and equipment – three to seven years; computer software – three years; and furniture and fixtures – five years.   Concentration of Risks   Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.   Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC health care products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.   Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.   We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2017, our cash balance was $37.3 million and our bank balance was $38.5 million. Of the total bank balance, $342,000 was covered by federal depository insurance and $38.1 million was uninsured at June 30, 2017.   Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due to us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2017 and December 31, 2016.   Long-lived Assets   We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.   Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.   Fair Value of Financial Instruments   Cash and cash equivalents, accounts receivable, assets held for sale, accounts payable, accrued expenses and notes payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value.   Revenue Recognition   Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.   Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.   Pursuant to the terms of the Asset Purchase Agreement, we are responsible for and continue to accept product returns of the Cold-EEZE® Business for product shipped prior to March 30, 2017. Additionally, pursuant to the terms of the Asset Purchase Agreement, we allocated and, in June 2017, issued a credit to Mylan in an aggregate of $400,000 for future sales returns and allowances arising from certain product returns that were sold by us prior to March 30, 2017.   As of June 30, 2017 and December 31, 2016, we included a provision for sales allowances of zero and $108,000, respectively. Additionally, accrued advertising and other allowances as of June 30, 2017 included (i) $934,000 for estimated future sales returns and (ii) $598,000 for cooperative incentive promotion costs. As of December 31, 2016, accrued advertising and other allowances included (i) $1.2 million for estimated future sales returns and (ii) $1.5 million for cooperative incentive promotion costs.   Advertising and Incentive Promotions   Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred (i) from continuing operations for the three months ended June 30, 2017 and 2016 were $21,000 and $139,000, respectively, and (ii) attributed to and classified as discontinued operations were $205,000 and $471,000, respectively. Advertising and incentive promotion expenses incurred (i) from continuing operations for the six months ended June 30, 2017 and 2016 were $53,000 and $339,000 , respectively, and (ii) attributed to and classified as discontinued operations were $2.8 million and $3.3 million, respectively. Included in prepaid expenses and other current assets was $17,000 and $263,000 at June 30, 2017 and December 31, 2016, respectively, relating to prepaid advertising and promotion expenses.   Shipping and Handling   Product sales may carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.   Stock-Based Compensation   We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.   Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three and six months ended June 30, 2017 and 2016, we charged to operations $18,000 and $1,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.   Research and Development   Research and development costs are charged to operations in the period incurred. Research and development costs incurred for the three months ended June 30, 2017 and 2016 (i) from continuing operations were $224,000 and $121,000, respectively, and (ii) attributed to and classified as discontinued operations of zero and $48,000, respectively. Research and development costs incurred for the six months ended June 30, 2017 and 2016 (i) from continuing operations were $258,000 and $160,000, respectively, and (ii) attributed to and classified as discontinued operations of $52,000 and $95,000, respectively. Research and development costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products.   Income Taxes   We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until we have sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a full valuation allowance equaling the total deferred tax asset is being provided (see Notes 3 and 6).   We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.   As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.   Recently Issued Accounting Standards   In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. This ASU, as amended, is effective for fiscal years and interim periods within those years beginning after December 15, 2017. We are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.   In February 2016, the FASB issued ASU No. 2016-02 “Leases”. The new standard will require most leases to be recognized on the balance sheet which will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter of fiscal 2019 and mandates a modified retrospective transition method. We do not intend to early adopt and are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.   In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses.” The standard modifies the impairment model for most financial assets, including trade accounts receivables and loans, and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. The effective date of the standard is for fiscal years beginning after December 15, 2019 with early adoption permitted. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.   In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance will be effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted including adoption in an interim period. We do not intend to early adopt and we are currently assessing the impact of adoption of this update will have on our consolidated financial statements.   In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other than Inventory”. The new standard requires entities should recognize the income tax consequences of an asset other than inventory when the asset transfer occurs. The new guidance will be effective for fiscal years beginning after December 15, 2017 and requires a modified retrospective adoption through a cumulative effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.

Note 3 – Discontinued Operations, Sale of the Cold-EEZE® Business   At the Special Meeting held on March 29, 2017, our stockholders approved the sale of the Cold-EEZE® Business and the transactions contemplated by the Asset Purchase Agreement. Effective March 29, 2017, we completed the sale of the Cold-EEZE® Business to Mylan.   As a consequence of the sale of the Cold-EEZE® Business, for the three and six months ended June 30, 2017 and 2016, we have classified as discontinued operations (i) the gain from the sale of the Cold-EEZE® Business, (ii) all gains and losses attributable to the Cold-EEZE® Business operations and (iii) the income tax expense attributed to the sale of the Cold-EEZE® Business (see Note 6). Excluded from the sale of the Cold-EEZE® Business were our accounts receivable and inventory, and we also retained all liabilities associated with our Cold-EEZE® Business operations arising prior to March 29, 2017.   Pursuant to the Asset Purchase Agreement, we also agreed to a one-time sale to Mylan of certain non-lozenge-based Cold-EEZE® inventory. At June 30, 2017, we classified as assets held for sale approximately $294,000 of such inventory, which approximates our cost. At December 31, 2016, the balance sheet impact of discontinued operations was deemed not material, as such, no reclassifications for discontinued operations have been presented.   Pursuant to the Asset Purchase Agreement, we entered into a 90 day transition service arrangement with Mylan, for which we earned $150,000 in transition service fees through June 30, 2017. Pursuant to this arrangement, we (i) received, processed, fulfilled, and shipped customer orders, and billed such customers for these shipments on behalf of Mylan from March 30, 2017 to June 30, 2017, (ii) processed certain sales allowances, returns and other customer promotional deductions, and (iii) paid certain Cold-EEZE® Business expenses which are to be reimbursed by Mylan. At June 30, 2017, we have a balance due to Mylan of $717,000 which is comprised of (i) net billings to Mylan’s customers for product shipments, less sales and other allowances, of $1.8 million (ii) return allocation of $400,000 for future sales returns and allowances (see Note 2), offset by (ii1) $1.4 million for product shipments and transition service fee due from Mylan and (iv) $106,000 for the reimbursement of certain Cold-EEZE® Business expenses we paid on behalf of Mylan. For the three and six months ended June 30, 2017, the $150,000 transition service fees earned are recorded as a component of other income (expense).   The net proceeds received from the sale of the Cold-EEZE® Business were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-left: 1.5pt; line-height: 107%">Gross consideration from the sale of the Cold-EEZE® Business</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">50,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Closing and transaction costs</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(4,175</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Net proceeds from sale of the Cold-EEZE® Business</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">45,825</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Book value of assets sold</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(13</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Gain on sale of the Cold-EEZE® Business before income taxes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">45,812</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Income tax expense</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(19,473</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Gain on sale of the Cold-EEZE® Business after income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">26,339</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Net proceeds:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Cash paid at closing, net of closing and transaction costs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">43,145</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Proceeds due on sale of assets, cash held in escrow  (see Note 8)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">48,145</td> <td style="line-height: 107%"> </td></tr> </table>   For the three and six months ended June 30, 2017, we incurred $10,000 and $4.2 million in closing and transaction costs associated with the sale of the Cold-EEZE® Business which were comprised of (i) transaction fees and related closing costs of $1.9 million and (ii) performance bonuses, contract termination compensation and severance payments to certain employees associated with the sale of the Cold-EEZE® Business of $2.3 million. The compensation committee of our board of directors approved these compensation arrangements. These compensation and termination payments were paid by us in April 2017.   The following table sets forth the condensed operating results of our discontinued operations for the three and six months ended June 30, 2017 and 2016, respectively, (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended June 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Six Months Ended June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 45%; padding-left: 1.5pt; line-height: 107%">Net sales</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(371</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">1,826</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">4,687</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">6,179</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Cost of sales</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">264</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">728</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,037</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,427</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Sales and marketing</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">533</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,833</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Administration</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">319</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">348</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">656</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Research and development</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">48</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">52</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">95</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Income (loss) from discontinued operations</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(835</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">198</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">530</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">168</td> <td style="line-height: 107%"> </td></tr> </table>

Note 4 – Secured Promissory Notes and Other Obligations   Secured Promissory Notes   On December 11, 2015, we executed two Subscription Agreements (the “Subscription Agreements”) with the investors named therein (the “Investors”) providing for the purchase of 12% Secured Promissory Notes – Series A (“Notes”) in the aggregate principal amount of up to $3.0 million and warrants to purchase shares of our Common Stock (the “Warrants”).   Notes in the amount of $1.5 million and 51,000 Warrants, at an exercise price of $1.35 per share, which was equal to the closing price of our Common Stock on the date of investment, were issued by the Company and its wholly-owned subsidiaries, PMI and Quigley Pharma, Inc. (collectively, the “Obligors”), and funded on December 11, 2015. We incurred loan origination costs of $22,000 which were recorded as a reduction of the Notes and the origination costs are charged to other income (expense) over the term of the loan. The Warrants had an exercise term equal to three years and were exercisable commencing on the date of issuance. The fair value of the Warrants at the date of grant was $14,000 which is recorded as a reduction of the Notes and is charged to other income (expense) over the term of the loan.   The Notes bore interest at the rate of 12% per annum, payable semi-annually and the principal is due and payable on June 15, 2017. The Notes could be pre-paid at any time prior to maturity without penalty. The effective interest, inclusive of the Warrant and loan origination costs, was 14.3% per annum. For the six months ended June 30, 2017 and 2016, we charged to other income (expense) $54,000 and $105,000, respectively, in connection with the Notes.   On March 29, 2017, in connection with the sale of the Cold-EEZE® Business, we paid in full the remaining principal and accrued interest, in the total amount of $1,553,000, due under the Notes. Of the $1,553,000 paid to the Investors, $69,000 was netted against the aggregate exercise price of the Warrants, which were simultaneously being exercised by the Investors.   In connection with the issuance of the Notes, the Company entered into a security agreement with John E. Ligums, Jr., as collateral agent for the Investors (the “Security Agreement”) to secure the timely payment and performance in full of the Company’s obligations under the Notes. Under the Security Agreement, we granted to the collateral agent, for the benefit of the Investors a lien upon and security interest in the property and assets listed as collateral in the Security Agreement, including without limitation, all of our personal property, inventory, equipment, general intangibles, cash and cash equivalents, and proceeds. In connection with the payoff of the Notes, the Security Agreement was terminated.

Note 5 – Transactions Affecting Stockholders’ Equity   Our authorized capital stock consists of 50 million shares of Common Stock and 1 million shares of preferred stock, $.0005 par value (“Preferred Stock”).   Preferred Stock   On June 16, 2015, our stockholders approved the change to our state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion (the “Conversion Plan”) and the filing of a certificate of incorporation in the State of Delaware. The Preferred Stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of June 30, 2017, no shares of Preferred Stock have been issued. Our board of directors has the full authority permitted by law to establish, without further stockholder approval, one or more series of Preferred Stock and the number of shares constituting each such series and to fix by resolution, voting powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any. Subject to the limitation on the total number of shares of Preferred Stock that we have authority to issue under our certificate of incorporation, the board of directors is also authorized to increase or decrease the number of shares of any series, subsequent to the issue of that series, but not below the number of shares of such series then-outstanding. In case the number of shares of any series is so decreased, the shares constituting such decrease will resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. We may amend from time to time our certificate of incorporation and bylaws to increase the number of authorized shares of Preferred Stock or Common Stock or to make other changes or additions to our capital structure or the terms of our capital stock.   Stockholder Rights Plan   On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to our stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009, (iii) June 18, 2014 and (iv) January 6, 2017. The Rights Agreement, as amended and restated, provides that each Right entitles the stockholder of record to purchase from the Company that number of shares of Common Stock having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of Common Stock, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding shares of Common Stock (such person, the “acquirer”). The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution.   The dividend has the effect of diluting the acquirer by giving our other stockholders a 50% discount on our Common Stock’s current market value for exercising the Rights. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one share of Common Stock of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.   Equity Line of Credit   On July 30, 2015, we entered into a new equity line of credit agreement (such arrangement, the “2015 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”). Pursuant to the 2015 Equity Line, Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,200,000 shares of our Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the Investment Agreement.   We may, at our discretion, draw on the 2015 Equity Line from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2015 Equity Line. The maximum number of shares that we are entitled to put to Dutchess in any one draw down notice shall not exceed 500,000 shares with a purchase price calculated in accordance with the terms of the 2015 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.   The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).   There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, we are entitled to deliver another draw down notice. In addition, Dutchess will not be obligated to purchase shares if Dutchess’ total number of shares beneficially held at that time would exceed 4.99% of the number of shares of Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.   Pursuant to the terms of the 2015 Equity Line, we are obligated to file one or more registration statements with the SEC to register the resale by Dutchess of the shares of Common Stock issued or issuable under the 2015 Equity Line. In addition, we are obligated to use all commercially reasonable efforts to have the registration statement declared effective by the SEC within 90 days after the registration statement is filed. On August 4, 2015, we filed a registration statement for the underlying shares of the 2015 Equity Line with the SEC and the registration statement was declared effective by the SEC on August 21, 2015.   At June 30, 2017, we have 2,450,000 shares of our Common Stock available for sale, at our discretion, under the terms of our 2015 Equity Line and covered pursuant to an effective registration statement.   The 2010 Equity Compensation Plan   On May 5, 2010, our stockholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by our stockholders on April 24, 2011, and further amended and approved by stockholders on May 6, 2013, and further amended and approved by stockholders on May 24, 2016 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 3.2 million shares, including 900,000 shares that are authorized for issuance but unissued under a 1997 incentive stock option plan and 700,000 shares added to the 2010 Plan effective May 24, 2016.   For the six month ended June 30, 2017 and 2016, we granted, 600,000 options, exercisable at $2.00 per share and subject to vesting over a four year term, and zero options, respectively, to employees to acquire our Common Stock pursuant to the terms of 2010 Plan. The assumptions used in determining the fair value of the 600,000 stock options granted in Fiscal 2017 were (i) expected option life of 4.5 years, (ii) weighted average risk rate of 1.81%, (iii) dividend yield of 0% and (iv) expected volatility of 44.51%.   For the six months ended June 30, 2017, 90,000 stock options were exercised pursuant to the 2010 Plan and we derived net proceeds of $102,000. For the six months ended June 30, 2016, there were no stock options exercised. At June 30, 2017, there were 2,209,000 options outstanding under the 2010 Plan and 133,659 options available to be issued pursuant to the terms of the 2010 Plan.   The 2010 Directors’ Equity Compensation Plan   On May 5, 2010, our stockholders approved the 2010 Directors’ Equity Compensation Plan, which was subsequently amended and approved by stockholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the six months ended June 30, 2017 and 2016, no shares were granted to our directors. At June 30, 2017, there were 147,808 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.   Treasury Stock Purchase Agreement   On June 12, 2017 we entered into a Stock Purchase Agreement with each of Mark S. Leventhal, a former director of the Company, and certain other persons and entities associated and/or affiliated with Mr. Leventhal (the “Leventhal Holders”), pursuant to which we purchased all 1,061,980 shares of our Common Stock then held by the Leventhal Holders, representing an approximate 6.2% aggregate ownership interest (based on 17,221,776 shares of common stock outstanding as of June 12, 2017). Upon consummation of the transactions, the Leventhal Holders ceased to hold any direct or indirect ownership interest in the Company.   Pursuant to the terms of the Stock Purchase Agreements, the total consideration paid by us to the Leventhal Holders for their shares was $1,858,465, which amount was equal to the product of (i) $1.75 multiplied by (ii) the number of shares purchased.

Note 6 – Income Taxes   At December 31, 2016, there were $47.1 million in net operating loss carryforwards, subject to applicable limitations, available to us for federal purposes which will expire beginning for the year ended December 31, 2020 through 2036. Additionally, there were $22.1 million in net operating loss carryforwards, subject to limitations, available to us for state purposes which will expire beginning for the year ended December 31, 2020 through 2036.   Based upon preliminary estimates, we believe that a significant portion of our income tax liability of $19.5 million arising from our taxable gain for federal and state income tax purposes from the sale of the Cold-EEZE® Business will be offset to the extent of our current year losses from operations, the write-off for tax purposes of the tax-basis of the Cold-EEZE® Business and the available net operating loss carryforwards at the federal and state levels. However, for state income tax purposes, based upon the available state net operating loss carryforwards and corresponding limitations, we estimate a net income tax expense arising from the sale of the Cold-EEZE® Business of $1.3 million.   Utilization of net operating loss carryforwards may be subject to limitations as set forth in Section 382 of the Internal Revenue Code (“Section 382”). Based on our preliminary Section 382 analysis, we do not believe that our current net operating loss carryforwards are subject to these limitations as of June 30, 2017. However, until we complete a final Section 382 analysis upon filing of our 2017 income tax return, there can be no assurances that our preliminary analysis is accurate or complete. Should we identify any limitations upon the completion of our final Section 382 analysis, the impact could be material to our consolidated financial statements and that we could incur additional income tax expense arising from the sale of the Cold-EEZE® Business.   For the six months ended June 30, 2017, we charged to discontinued operations $19.5 million for estimated federal and state income taxes arising from the sale of the Cold-EEZE® Business and we have realized an income tax benefit from continuing operations of $18.1 million as a consequence of the utilization of the federal and state net operating losses.   Subsequent to the income tax effects arising from the sale of the Cold-EEZE® Business, we will continue to have net operating loss carry-forwards for federal income tax purposes. Until sufficient taxable income to offset the temporary timing differences attributable to operations, and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided. As a consequence of the accumulated losses of the Company, we believe that this allowance is required due to the uncertainty of realizing these tax benefits in the future.

Note 8 – Earnings (Loss) Per Share   Basic earnings (loss) per share for continuing and discontinued operations are computed by dividing respective net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at June 30, 2017 and 2016 were 2,209,000 and 1,706,500, respectively.   For the three months ended June 30, 2017 and June 30, 2016 dilutive earnings (loss) per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended June 30, 2017 and 2016 there were 641,754 and 276,165, Common Stock Equivalents which were in the money, that were excluded from the earnings (loss) per share computation as a consequence of their anti-dilutive effect.   For the six months ended June 30, 2017 there were 650,190 Common Stock Equivalents which were in the money, that were included in the fully diluted earnings per share computation. For the six months ended June 30, 2016, for continuing operations dilutive earnings (loss) per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the six months ended June 30, 2016, there were 244,112, Common Stock Equivalents which were in the money, that were excluded from the earnings (loss) per share computation as a consequence of their anti-dilutive effect.

1900000

4200000

10000

2209000 1706500

48145000

5770000

1835000

2736000

1966000

680000

849000

294000

9627000

42224000

3175000

2875000

12802000

50099000

1490000

2156000

916000

2805000

1551000

389000

289000

6840000

3473000

13000

56378000

56567000

-19687000

22646000

30742000

32600000

12802000

50099000

2676000

2037000

1905000

1021000

2451000

1723000

1765000

993000

225000

314000

140000

28000

336000

534000

221000

236000

2387000

2146000

1306000

943000

2981000

2840000

1751000

1300000

-2659000 -2631000 -1460000 -1325000

15464000

-2631000

-1460000

-1325000

-530000

-168000

835000

-198000

26869000

168000

-845000

198000

0.91

-0.15

-0.09

-0.08

1.58

0.01

-0.05

0.01

0.87

-0.15

-0.09

-0.08

1.52

0.01

-0.05

0.01

17030000

17081000

16943000

17081000

17680000

17081000

16943000

17081000

97000

-105000

151000

-53000

90000

102000

-1061980

-1858000

18000

26339000

419000

213000

-10000

-12000

18000

1000

-3935000

-2199000

-770000

18000

169000

-703000

-1240000

382000

-1254000 -621000

-100000

-596000

294000

-667000

-188000

40825000

132000

327000

40693000

-327000

1500000

-3187000

36839000

-515000

441000

37280000

1149000

1664000

54000

95000

1858000

1350000

37300000

38500000

342000

38100000

150000

1400000

106000

717000

1800000 0.15 0.20 0.50

0.50

0.062

2024-06-18 3200000 500000 The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%). 0.0499

2450000

3200000

700000

900000

600000

2.00

P4Y

P4Y6M

0.0181

0.00

0.4451

90000

425000

1061980 1858465

1.75

If, on the 18th month anniversary of the closing date, there are funds remaining in the escrow account, then the escrow account will be reduced by the difference, if a positive number, of (i) $2.5 million minus (ii) the aggregate amount of all escrow claims asserted by Mylan prior to this date that have either been paid out of the escrow account or are pending as of such date, and, within two business days of such date, the Escrow Agent will disburse such difference, if a positive number, to us. Within two business days of the second anniversary of the closing date, the Escrow Agent will release any funds remaining in the escrow account to us minus any amounts being reserved for escrow claims asserted by Mylan prior to such date. Upon the resolution of any pending escrow claims, the Escrow Agent will, within two business days of receipt of joint instructions or a final order from a court (as described in the Escrow Agreement) disburse such reserved amount to the parties entitled to such funds.

338000

675000

1013000

Note 7– Commitments and Contingencies   Escrow Receivable   We have indemnification obligations to Mylan under the Asset Purchase Agreement that may require us to make future payments to Mylan and other related persons for any damages incurred by Mylan or such related persons as a result of any breaches of our representations, warranties, covenants or agreements contained in the Asset Purchase Agreement, or arising from the Retained Liabilities (as such term is defined in the Asset Purchase Agreement) or certain third party claims specified in the Asset Purchase Agreement. Generally, our representations and warranties survive for a period of 24 months from the closing date, other than certain fundamental representations which survive until the expiration of the applicable statute of limitations. There is a limited indemnification cap with respect to a majority of the Company’s indemnification obligations under the Asset Purchase Agreement with the exception of claims for actual fraud, the breach of any fundamental representations and certain other items, which have a larger indemnification cap (e.g., the purchase price).   Pursuant to the terms of the Asset Purchase Agreement, we, Mylan, and an escrow agent entered into an Escrow Agreement at closing, pursuant to which Mylan deposited $5 million of the aggregate purchase price for the Cold-EEZE® Business into an escrow account established with the Escrow Agent in order to satisfy, in whole or in part, certain of our indemnity obligations under the Asset Purchase Agreement. If, on the 18th month anniversary of the closing date, there are funds remaining in the escrow account, then the escrow account will be reduced by the difference, if a positive number, of (i) $2.5 million minus (ii) the aggregate amount of all escrow claims asserted by Mylan prior to this date that have either been paid out of the escrow account or are pending as of such date, and, within two business days of such date, the Escrow Agent will disburse such difference, if a positive number, to us. Within two business days of the second anniversary of the closing date, the Escrow Agent will release any funds remaining in the escrow account to us minus any amounts being reserved for escrow claims asserted by Mylan prior to such date. Upon the resolution of any pending escrow claims, the Escrow Agent will, within two business days of receipt of joint instructions or a final order from a court (as described in the Escrow Agreement) disburse such reserved amount to the parties entitled to such funds.   Management does not believe that we will be subject to indemnity claims contemplated by the Asset Purchase Agreement. However, in the event that such a claim is made, and if successful, we would be required to pay Mylan pursuant to the indemnification provisions of the Asset Purchase Agreement which may reduce the amount we ultimately collect from escrow or could even require us to return a portion of the net proceeds received from the sale of the Cold-EEZE® Division.   Manufacturing Agreement   In connection with the Asset Purchase Agreement, the Company and its wholly-owned subsidiary, PMI, entered into a Manufacturing Agreement (the “Manufacturing Agreement”) with Mylan. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) will purchase the inventory of the Company’s Cold-EEZE® brand and product line and PMI will manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2022. Thereafter, the Manufacturing Agreement may be renewed by Mylan for up to five successive one year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.   Transition Services Agreement   In connection with the Asset Purchase Agreement, we entered into a transition services agreement with Mylan to provide litigation support, insurance coverage, supply chain, customer support, finance, accounting, commercial advertising and packaging services, quality control, IT and research and development services to Mylan for time periods ranging from two to nine months from the closing date. We will continue to incur certain operating costs during the transition period to support Mylan.   Future Obligations:   We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2017, as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Fiscal year</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Employment Contracts</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; text-align: center; line-height: 107%">2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 26%; text-align: right; line-height: 107%">338</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">675</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 60pt; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,013</td> <td style="line-height: 107%"> </td></tr> </table>

Basis of Presentation   The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of operating results that may be achieved over the course of the full year. Historical financial statements have been reclassified to conform to the current period presentation, principally reflecting the sale of Cold-EEZE® Business as discontinued operations.

Discontinued Operations Carve Out and ProPhase Allocations   For the three and six months ended June 30, 2017 and 2016, results from operations for our Cold-EEZE® Business are classified as discontinued operations The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, net sales, cost of sales, operating expenses and interest expense associated with the Cold-EEZE® Business’s operations. General administrative and overhead expenses, including personnel expenses and bonuses, and research and development overhead expenses incurred by us (for which the discontinued operation benefits from such resources) are allocated to discontinued operations based upon the percentage of the Cold-EEZE® Business’s net sales to our consolidated net sales. For the three months ended June 30, 2017 and 2016, we allocated (i) zero and $319,000, respectively, of administrative expenses and (ii) zero and $48,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations. For the six months ended June 30, 2017 and 2016, we allocated (i) $348,000 and $656,000, respectively, of administrative expenses and (ii) $52,000 and $95,000, respectively, of research and development expenses, to discontinued operations in the accompanying condensed statements of operations (see Note 3).

Seasonality of the Business   Our net sales are derived principally from our OTC heath care and cold remedy products sold in the United States of America. Our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net sales. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.   For the three and six months ended June 30, 2017 and 2016, our net sales were principally related to domestic markets.

Use of Estimates   The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment, impairment of property and equipment, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Cash and Cash Equivalents   We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation   Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2017 and December 31, 2016, the financial statements include adjustments to reduce inventory for excess or obsolete inventory of $1.7 million and $1.6 million, respectively. The components of inventory are as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; text-align: justify; line-height: 107%">Raw materials</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">1,590</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">1,404</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Work in process</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">342</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">466</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">34</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">866</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,966</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,736</td> <td style="line-height: 107%"> </td></tr> </table>

Property, Plant and Equipment   Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements – ten to thirty-nine years; machinery and equipment – three to seven years; computer software – three years; and furniture and fixtures – five years.

Concentration of Risks   Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.   Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC health care products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.   Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.   We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2017, our cash balance was $37.3 million and our bank balance was $38.5 million. Of the total bank balance, $342,000 was covered by federal depository insurance and $38.1 million was uninsured at June 30, 2017.   Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due to us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2017 and December 31, 2016.

Long-lived Assets   We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.   Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments   Cash and cash equivalents, accounts receivable, assets held for sale, accounts payable, accrued expenses and notes payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value.

Revenue Recognition   Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.   Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.   Pursuant to the terms of the Asset Purchase Agreement, we are responsible for and continue to accept product returns of the Cold-EEZE® Business for product shipped prior to March 30, 2017. Additionally, pursuant to the terms of the Asset Purchase Agreement, we allocated and, in June 2017, issued a credit to Mylan in an aggregate of $400,000 for future sales returns and allowances arising from certain product returns that were sold by us prior to March 30, 2017.   As of June 30, 2017 and December 31, 2016, we included a provision for sales allowances of zero and $108,000, respectively. Additionally, accrued advertising and other allowances as of June 30, 2017 included (i) $934,000 for estimated future sales returns and (ii) $598,000 for cooperative incentive promotion costs. As of December 31, 2016, accrued advertising and other allowances included (i) $1.2 million for estimated future sales returns and (ii) $1.5 million for cooperative incentive promotion costs.

Advertising and Incentive Promotions   Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred (i) from continuing operations for the three months ended June 30, 2017 and 2016 were $21,000 and $139,000, respectively, and (ii) attributed to and classified as discontinued operations were $205,000 and $471,000, respectively. Advertising and incentive promotion expenses incurred (i) from continuing operations for the six months ended June 30, 2017 and 2016 were $53,000 and $339,000 , respectively, and (ii) attributed to and classified as discontinued operations were $2.8 million and $3.3 million, respectively. Included in prepaid expenses and other current assets was $17,000 and $263,000 at June 30, 2017 and December 31, 2016, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling   Product sales may carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock-Based Compensation   We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.   Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three and six months ended June 30, 2017 and 2016, we charged to operations $18,000 and $1,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Research and Development   Research and development costs are charged to operations in the period incurred. Research and development costs incurred for the three months ended June 30, 2017 and 2016 (i) from continuing operations were $224,000 and $121,000, respectively, and (ii) attributed to and classified as discontinued operations of zero and $48,000, respectively. Research and development costs incurred for the six months ended June 30, 2017 and 2016 (i) from continuing operations were $258,000 and $160,000, respectively, and (ii) attributed to and classified as discontinued operations of $52,000 and $95,000, respectively. Research and development costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products.

Income Taxes   We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until we have sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a full valuation allowance equaling the total deferred tax asset is being provided (see Notes 3 and 6).   We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to income taxes will be recorded as interest or administrative expense, respectively.   As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards   In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. This ASU, as amended, is effective for fiscal years and interim periods within those years beginning after December 15, 2017. We are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.   In February 2016, the FASB issued ASU No. 2016-02 “Leases”. The new standard will require most leases to be recognized on the balance sheet which will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter of fiscal 2019 and mandates a modified retrospective transition method. We do not intend to early adopt and are currently assessing the impact of this update, but preliminarily believe that its adoption will not have a material impact on our consolidated financial statements.   In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses.” The standard modifies the impairment model for most financial assets, including trade accounts receivables and loans, and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. The effective date of the standard is for fiscal years beginning after December 15, 2019 with early adoption permitted. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.   In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance will be effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted including adoption in an interim period. We do not intend to early adopt and we are currently assessing the impact of adoption of this update will have on our consolidated financial statements.   In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other than Inventory”. The new standard requires entities should recognize the income tax consequences of an asset other than inventory when the asset transfer occurs. The new guidance will be effective for fiscal years beginning after December 15, 2017 and requires a modified retrospective adoption through a cumulative effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of adoption of this update on our consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-left: 1.5pt; line-height: 107%">Gross consideration from the sale of the Cold-EEZE® Business</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">50,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Closing and transaction costs</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(4,175</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Net proceeds from sale of the Cold-EEZE® Business</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">45,825</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Book value of assets sold</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(13</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Gain on sale of the Cold-EEZE® Business before income taxes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">45,812</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Income tax expense</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(19,473</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Gain on sale of the Cold-EEZE® Business after income taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">26,339</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Net proceeds:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Cash paid at closing, net of closing and transaction costs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">43,145</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Proceeds due on sale of assets, cash held in escrow  (see Note 8)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">48,145</td> <td style="line-height: 107%"> </td></tr> </table>

The following table sets forth the condensed operating results of our discontinued operations for the three and six months ended June 30, 2017 and 2016, respectively, (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended June 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Six Months Ended June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 45%; padding-left: 1.5pt; line-height: 107%">Net sales</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(371</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">1,826</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">4,687</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">6,179</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Cost of sales</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">264</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">728</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,037</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,427</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Sales and marketing</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">533</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,720</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,833</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Administration</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">319</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">348</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">656</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Research and development</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">48</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">52</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">95</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Income (loss) from discontinued operations</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(835</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">198</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">530</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">168</td> <td style="line-height: 107%"> </td></tr> </table>

2017

2.49

-0.14

-0.07

2.39

-0.14

-0.07

69000 0 69000 5000000

2300000

16166796

400000

45825000 5000000 -19473000 717000 717000

EX-101.SCH 7 prph-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE® Business link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Secured Promissory Notes and Other Obligations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Transactions Affecting Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE® Business (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE® Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE® Business - Schedule of Proceeds from Sale of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE® Business - Schedule of Operating Results of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Secured Promissory Notes and Other Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Transactions Affecting Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Commitments and Contingencies - Schedule of Estimated Future Minimum Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Earnings (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 prph-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 prph-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 prph-20170630_lab.xml XBRL LABEL FILE Valuation Allowances and Reserves Type [Axis] Estimated Future Sales Return [Member] Loss Contingency Nature [Axis] Employment Contracts [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Plan Name [Axis] 2010 Equity Compensation Plan [Member] Short-term Debt, Type [Axis] 2015 Equity Line of Credit [Member] Legal Entity [Axis] Dutchess [Member] Debt Instrument [Axis] Secured Promissory Notes [Member] Equity Components [Axis] Common Stock Shares Outstanding, Net of Shares of Treasury Stock [Member] Additional Paid-In Capital [Member] Retained Earnings (Accum. Deficit) [Member] Treasury Stock [Member] Property, Plant and Equipment, Type [Axis] Machinery and Equipment [Member] Range [Axis] Minimum [Member] Maximum [Member] Furniture and Fixtures [Member] Stockholder Rights Plan [Member] 2010 Directors' Equity Compensation Plan [Member] Related Party [Axis] Chairman and Chief Executive Officer [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Rights Agreement [Member] Operating Activities [Axis] Discontinued Operations [Member] Cold-EEZE® Business [Member] Investors [Member] 1997 Equity Compensation Plan [Member] Mylan and Escrow Agent [Member] Escrow Agreement [Member] Cooperative Incentive [Member] Building and Improvements [Member] Computer Software [Member] Asset Purchase Agreement [Member] Mylan [Member] Title of Individual [Axis] Employees [Member] 2010 Plan [Member] Stock Purchase Agreement [Member] Leventhal Holders [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Cash and cash equivalents (Note 2) Accounts receivable, net (Note 2) Inventory (Note 2) Prepaid expenses and other current assets (Note 2) Assets held for sale (Note 3) Total current assets Property, plant and equipment, net of accumulated depreciation of $5,274 and $5,134, respectively (Note 2) Escrow receivable Total assets LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Secured promissory notes, net (Note 4) Accounts payable Accrued advertising and other allowances (Note 2) Other current liabilities Due to Mylan, Inc. and affiliates (Note 3) Total current liabilities COMMITMENTS AND CONTINGENCIES (Note 7) STOCKHOLDERS' EQUITY Preferred stock, authorized 1,000,000, $.0005 par value, no shares issued (Note 5) Common stock, $.0005 par value; authorized 50,000,000; issued: 26,454,593 and 26,313,593 shares, respectively (Note 5) Additional paid-in-capital Retained earnings (Accumulated deficit) Treasury stock, at cost, 10,294,797 and 9,232,817 shares (Note 5) Total stockholders' equity Total liabilities and stockholders' equity Accumulated depreciation Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Common stock, par value Common stock, shares authorized Common stock, shares issued Treasury stock, shares Income Statement [Abstract] Net sales (Note 2) Cost of sales (Note 2) Gross profit Operating expenses (Note 2): Sales and marketing Administration Research and development Total operating expenses Other income (expense), net Loss from continuing operations before income taxes (Note 6) Income tax benefit from continuing operations Income (loss) from continuing operations Discontinued operations (Note 3): Income (loss) from discontinued operations Gain on sale of discontinued operations, net of taxes Income (loss) from discontinued operations Net income (loss) Basic earnings (loss) per share: Income (loss) from continuing operations Income (loss) from discontinued continued operations Net income (loss) Diluted earnings (loss) per share: Income (loss) from continuing operations Income (loss) from discontinued continued operations Net income (loss) Weighted average common shares outstanding: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Net income Proceeds from warrants exercised Proceeds from warrants exercised, shares Proceeds from options exercised Proceeds from options exercised, shares Treasury stock acquired Treasury stock acquired, shares Share-based compensation expense Tax benefit from exercise of warrants Tax benefit allowance Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Gain on sale of assets, net of taxes Change in valuation allowance, income tax Depreciation and amortization Amortization of loan origination and warrant expenses Share-based compensation expense Changes in continuing operating assets and liabilities: Accounts receivable Inventory Prepaid and other assets Accounts payable Accrued advertising and other allowances Due to Mylan, Inc. and affiliates Other current liabilities Changes in discontinued operation assets and liabilities: Assets held for sale Net cash used in operating activities Cash flows from investing activities: Net proceeds from the sale of asset Capital expenditures Net cash provided by (used in) investing activities Cash flows from financing activities: Payments to retire Notes Payments to acquire treasury stock Proceeds from exercise of warrants and stock options Net cash used in financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosures of cash flow information: Interest paid Income taxes paid Non-cash investing activities: Escrow receivable Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Sale of the Cold-EEZE® Business Debt Disclosure [Abstract] Secured Promissory Notes and Other Obligations Equity [Abstract] Transactions Affecting Stockholders' Equity Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Earnings Per Share [Abstract] EX-101.PRE 11 prph-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 11, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	ProPhase Labs, Inc.
Entity Central Index Key	0000868278
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,166,796
Trading Symbol	PRPH
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents (Note 2)	$ 37,280	$ 441
Accounts receivable, net (Note 2)	1,835	5,770
Inventory (Note 2)	1,966	2,736
Prepaid expenses and other current assets (Note 2)	849	680
Assets held for sale (Note 3)	294
Total current assets	42,224	9,627
Property, plant and equipment, net of accumulated depreciation of $5,274 and $5,134, respectively (Note 2)	2,875	3,175
Escrow receivable	5,000
Total assets	50,099	12,802
LIABILITIES
Secured promissory notes, net (Note 4)		1,490
Accounts payable	916	2,156
Accrued advertising and other allowances (Note 2)	1,551	2,805
Other current liabilities	289	389
Due to Mylan, Inc. and affiliates (Note 3)	717
Total current liabilities	3,473	6,840
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY
Preferred stock, authorized 1,000,000, $.0005 par value, no shares issued (Note 5)
Common stock, $.0005 par value; authorized 50,000,000; issued: 26,454,593 and 26,313,593 shares, respectively (Note 5)	13	13
Additional paid-in-capital	56,567	56,378
Retained earnings (Accumulated deficit)	22,646	(19,687)
Treasury stock, at cost, 10,294,797 and 9,232,817 shares (Note 5)	(32,600)	(30,742)
Total stockholders' equity	46,626	5,962
Total liabilities and stockholders' equity	$ 50,099	$ 12,802

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 5,274	$ 5,134
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, par value	$ 0.0005	$ 0.0005
Preferred stock, shares issued
Common stock, par value	$ 0.0005	$ 0.0005
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	26,454,593	26,313,593
Treasury stock, shares	10,294,797	9,232,817

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net sales (Note 2)	$ 1,905	$ 1,021	$ 2,676	$ 2,037
Cost of sales (Note 2)	1,765	993	2,451	1,723
Gross profit	140	28	225	314
Operating expenses (Note 2):
Sales and marketing	221	236	336	534
Administration	1,306	943	2,387	2,146
Research and development	224	121	258	160
Total operating expenses	1,751	1,300	2,981	2,840
Other income (expense), net	151	(53)	97	(105)
Loss from continuing operations before income taxes (Note 6)	(1,460)	(1,325)	(2,659)	(2,631)
Income tax benefit from continuing operations			18,123
Income (loss) from continuing operations	(1,460)	(1,325)	15,464	(2,631)
Discontinued operations (Note 3):
Income (loss) from discontinued operations	(835)	198	530	168
Gain on sale of discontinued operations, net of taxes	(10)		26,339
Income (loss) from discontinued operations	(845)	198	26,869	168
Net income (loss)	$ (2,305)	$ (1,127)	$ 42,333	$ (2,463)
Basic earnings (loss) per share:
Income (loss) from continuing operations	$ (0.09)	$ (0.08)	$ 0.91	$ (0.15)
Income (loss) from discontinued continued operations	(0.05)	0.01	1.58	0.01
Net income (loss)	(0.14)	(0.07)	2.49	(0.14)
Diluted earnings (loss) per share:
Income (loss) from continuing operations	(0.09)	(0.08)	0.87	(0.15)
Income (loss) from discontinued continued operations	(0.05)	0.01	1.52	0.01
Net income (loss)	$ (0.14)	$ (0.07)	$ 2.39	$ (0.14)
Weighted average common shares outstanding:
Basic	16,943,000	17,081,000	17,030,000	17,081,000
Diluted	16,943,000	17,081,000	17,680,000	17,081,000

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($)	Common Stock Shares Outstanding, Net of Shares of Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accum. Deficit) [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2016	$ 13,000	$ 56,378,000	$ (19,687,000)	$ (30,742,000)	$ 5,962,000
Balance, shares at Dec. 31, 2016	17,080,776
Net income			42,333,000		42,333,000
Proceeds from warrants exercised	$ 0	69,000			69,000
Proceeds from warrants exercised, shares	51,000
Proceeds from options exercised		102,000			102,000
Proceeds from options exercised, shares	90,000
Treasury stock acquired				(1,858,000)	(1,858,000)
Treasury stock acquired, shares	(1,061,980)
Share-based compensation expense		18,000			18,000
Tax benefit from exercise of warrants		43,000			43,000
Tax benefit allowance		(43,000)			(43,000)
Balance at Jun. 30, 2017	$ 13,000	$ 56,567,000	$ 22,646,000	$ (32,600,000)	$ 46,626,000
Balance, shares at Jun. 30, 2017	16,159,796

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 42,333	$ (2,463)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Gain on sale of assets, net of taxes	(26,339)
Change in valuation allowance, income tax	(19,473)
Depreciation and amortization	419	213
Amortization of loan origination and warrant expenses	10	12
Share-based compensation expense	18	1
Changes in continuing operating assets and liabilities:
Accounts receivable	3,935	2,199
Inventory	770	(18)
Prepaid and other assets	(169)	703
Accounts payable	(1,240)	382
Accrued advertising and other allowances	(1,254)	(621)
Due to Mylan, Inc. and affiliates	717
Other current liabilities	(100)	(596)
Changes in discontinued operation assets and liabilities:
Assets held for sale	(294)
Net cash used in operating activities	(667)	(188)
Cash flows from investing activities:
Net proceeds from the sale of asset	40,825
Capital expenditures	(132)	(327)
Net cash provided by (used in) investing activities	40,693	(327)
Cash flows from financing activities:
Payments to retire Notes	(1,500)
Payments to acquire treasury stock	(1,858)
Proceeds from exercise of warrants and stock options	171
Net cash used in financing activities	(3,187)
Net increase (decrease) in cash and cash equivalents	36,839	(515)
Cash and cash equivalents at beginning of period	441	1,664
Cash and cash equivalents at end of period	37,280	1,149
Supplemental disclosures of cash flow information:
Interest paid	54	95
Income taxes paid	1,350
Non-cash investing activities:
Escrow receivable	$ 5,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Business

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

Note 1 – Organization and Business

Discontinued Operations

Continuing Operations

For the three and six months ended June 30, 2017 and 2016, our revenues from continuing operations have come principally from our OTC health care products.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

Discontinued Operations Carve Out and ProPhase Allocations

Seasonality of the Business

For the three and six months ended June 30, 2017 and 2016, our net sales were principally related to domestic markets.

Use of Estimates

Cash and Cash Equivalents

Inventory Valuation

	June 30, 2017		December 31, 2016
Raw materials	$	1,590	$	1,404
Work in process		342		466
Finished goods		34		866
	$	1,966	$	2,736

Property, Plant and Equipment

Concentration of Risks

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

Long-lived Assets

Fair Value of Financial Instruments

Revenue Recognition

Advertising and Incentive Promotions

Shipping and Handling

Stock-Based Compensation

Research and Development

Income Taxes

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards

XML 20 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations, Sale of the Cold-EEZE® Business

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations, Sale of the Cold-EEZE® Business

Note 3 – Discontinued Operations, Sale of the Cold-EEZE^® Business

The net proceeds received from the sale of the Cold-EEZE^® Business were as follows (in thousands):

	Amount
Gross consideration from the sale of the Cold-EEZE^®Business	$	50,000
Closing and transaction costs		(4,175	)
Net proceeds from sale of the Cold-EEZE^® Business		45,825
Book value of assets sold		(13	)
Gain on sale of the Cold-EEZE^® Business before income taxes		45,812
Income tax expense		(19,473	)
Gain on sale of the Cold-EEZE^® Business after income taxes	$	26,339

Net proceeds:
Cash paid at closing, net of closing and transaction costs	$	43,145
Proceeds due on sale of assets, cash held in escrow (see Note 8)		5,000
	$	48,145

The following table sets forth the condensed operating results of our discontinued operations for the three and six months ended June 30, 2017 and 2016, respectively, (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2017			2016		2017		2016
Net sales	$	(371	)	$	1,826	$	4,687	$	6,179
Cost of sales		264			728		2,037		2,427
Sales and marketing		200			533		1,720		2,833
Administration		-			319		348		656
Research and development		-			48		52		95
Income (loss) from discontinued operations	$	(835	)	$	198	$	530	$	168

XML 21 R10.htm IDEA: XBRL DOCUMENT

Secured Promissory Notes and Other Obligations

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Secured Promissory Notes and Other Obligations

Note 4 – Secured Promissory Notes and Other Obligations

Secured Promissory Notes

XML 22 R11.htm IDEA: XBRL DOCUMENT

Transactions Affecting Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Transactions Affecting Stockholders' Equity

Note 5 – Transactions Affecting Stockholders’ Equity

Our authorized capital stock consists of 50 million shares of Common Stock and 1 million shares of preferred stock, $.0005 par value (“Preferred Stock”).

Preferred Stock

Stockholder Rights Plan

Equity Line of Credit

The 2010 Equity Compensation Plan

The 2010 Directors’ Equity Compensation Plan

Treasury Stock Purchase Agreement

XML 23 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Note 6 – Income Taxes

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7– Commitments and Contingencies

Escrow Receivable

Manufacturing Agreement

Transition Services Agreement

Future Obligations:

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2017, as follows (in thousands):

Fiscal year	Employment Contracts
2017		338
2018		675
2019		-
2020		-
2021		-
Total	$	1,013

XML 25 R14.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Note 8 – Earnings (Loss) Per Share

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Discontinued Operations Carve Out and ProPhase Allocations

Discontinued Operations Carve Out and ProPhase Allocations

Seasonality of the Business

Seasonality of the Business

For the three and six months ended June 30, 2017 and 2016, our net sales were principally related to domestic markets.

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Inventory Valuation

Inventory Valuation

	June 30, 2017		December 31, 2016
Raw materials	$	1,590	$	1,404
Work in process		342		466
Finished goods		34		866
	$	1,966	$	2,736

Property, Plant and Equipment

Property, Plant and Equipment

Concentration of Risks

Concentration of Risks

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

Long-lived Assets

Long-lived Assets

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Revenue Recognition

Revenue Recognition

Advertising and Incentive Promotions

Advertising and Incentive Promotions

Shipping and Handling

Shipping and Handling

Stock-Based Compensation

Stock-Based Compensation

Research and Development

Research and Development

Income Taxes

Income Taxes

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Components of Inventory

The components of inventory are as follows (in thousands):

	June 30, 2017		December 31, 2016
Raw materials	$	1,590	$	1,404
Work in process		342		466
Finished goods		34		866
	$	1,966	$	2,736

XML 28 R17.htm IDEA: XBRL DOCUMENT

Discontinued Operations, Sale of the Cold-EEZE® Business (Tables)

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Proceeds from Sale of Business

	Amount
Gross consideration from the sale of the Cold-EEZE^®Business	$	50,000
Closing and transaction costs		(4,175	)
Net proceeds from sale of the Cold-EEZE^® Business		45,825
Book value of assets sold		(13	)
Gain on sale of the Cold-EEZE^® Business before income taxes		45,812
Income tax expense		(19,473	)
Gain on sale of the Cold-EEZE^® Business after income taxes	$	26,339

Net proceeds:
Cash paid at closing, net of closing and transaction costs	$	43,145
Proceeds due on sale of assets, cash held in escrow (see Note 8)		5,000
	$	48,145

Schedule of Operating Results of Discontinued Operations

The following table sets forth the condensed operating results of our discontinued operations for the three and six months ended June 30, 2017 and 2016, respectively, (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2017			2016		2017		2016
Net sales	$	(371	)	$	1,826	$	4,687	$	6,179
Cost of sales		264			728		2,037		2,427
Sales and marketing		200			533		1,720		2,833
Administration		-			319		348		656
Research and development		-			48		52		95
Income (loss) from discontinued operations	$	(835	)	$	198	$	530	$	168

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Estimated Future Minimum Obligations

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2017, as follows (in thousands):

Fiscal year	Employment Contracts
2017		338
2018		675
2019		-
2020		-
2021		-
Total	$	1,013

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Administrative expense		$ 319	$ 348	$ 656
Research and development discontinued operation		48	52	95
Adjustments to reduce inventory for excess or obsolete inventory	1,700		1,700		$ 1,600
Cash balance	37,300		37,300
Bank balance	38,500		38,500
Amount of bank balance covered by federal depository insurance	342		342
Amount of bank balance uninsured	38,100		38,100
Allowance for bad debt
Accrued liabilities	400		400
Provision for sales allowances			0		108
Advertising and incentive promotion expenses	21	139	53	339
Prepaid expenses and other current assets	$ 17		$ 17		$ 263
Common stock par value	$ 0.0005		$ 0.0005		$ 0.0005
Stock option exercisable period			10 years
Share-based compensation expense	$ 18	1	$ 18	1
Research and development	224	121	258	160
Discontinued Operations [Member]
Advertising and incentive promotion expenses	205	471	2,800	3,300
Research and development	0	$ 48	52	$ 95
Estimated Future Sales Return [Member]
Accrued liabilities	$ 934		934		$ 1,200
Cooperative Incentive [Member]
Advertising and incentive promotion expenses			$ 598		$ 1,500
Building and Improvements [Member] \| Minimum [Member]
Property, plant and equipment, useful life			10 years
Building and Improvements [Member] \| Maximum [Member]
Property, plant and equipment, useful life			39 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, plant and equipment, useful life			3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, plant and equipment, useful life			7 years
Computer Software [Member]
Property, plant and equipment, useful life			3 years
Furniture and Fixtures [Member]
Property, plant and equipment, useful life			5 years

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Raw materials	$ 1,590	$ 1,404
Work in process	342	466
Finished goods	34	866
Total inventory	$ 1,966	$ 2,736

XML 32 R21.htm IDEA: XBRL DOCUMENT

Discontinued Operations, Sale of the Cold-EEZE® Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Assets held for sale	$ 294	$ 294
Transition service fees	150	150
Closing and transaction costs		1,900
Cold-EEZE® Business [Member]
Closing and transaction costs		4,200
Employees related compensation		2,300
Asset Purchase Agreement [Member]
Assets held for sale	294	294
Transition service fees		150
Asset Purchase Agreement [Member] \| Mylan [Member]
Transition service fees		1,400
Due to related party	717	717
Sales and other allowances	1,800	1,800
Sales return allocation		400
Reimbursement expenses		$ 106
Closing and transaction costs	$ 10

XML 33 R22.htm IDEA: XBRL DOCUMENT

Discontinued Operations, Sale of the Cold-EEZE® Business - Schedule of Proceeds from Sale of Business (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Gross consideration from the sale of the Cold-EEZE® Business			$ 50,000
Closing and transaction costs			(4,175)
Net proceeds from sale of the Cold-EEZE® Business			45,825
Book value of assets sold			(13)
Gain on sale of the Cold-EEZE® Business before income taxes			45,812
Income tax expense			(19,473)
Gain on sale of the Cold-EEZE® Business after income taxes	$ (10)		26,339
Cash paid at closing, net of closing and transaction costs			43,145
Proceeds due on sale of assets, cash held in escrow (see Note 8)			5,000
Net proceeds from the sale of assets			$ 48,145

XML 34 R23.htm IDEA: XBRL DOCUMENT

Discontinued Operations, Sale of the Cold-EEZE® Business - Schedule of Operating Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Net sales	$ (371)	$ 1,826	$ 4,687	$ 6,179
Cost of sales	264	728	2,037	2,427
Sales and marketing	200	533	1,720	2,833
Administration		319	348	656
Research and development		48	52	95
Income (loss) from discontinued operations	$ (835)	$ 198	$ 530	$ 168

XML 35 R24.htm IDEA: XBRL DOCUMENT

Secured Promissory Notes and Other Obligations (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Mar. 29, 2017	Dec. 11, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 15, 2017
Notes bear interest at rate per annum		12.00%			12.00%
Proceeds from notes payable		$ 1,500
Class of warrants issued during period		51,000
Warrants exercise price per share		$ 1.35
Incurred loan origination costs		$ 22
Warrant exercise term		3 years
Fair value of warrants		$ 14
Debt instruments maturity date		Jun. 15, 2017
Percentage of warrant and loan origination costs		14.30%
Interest expense			$ 54	$ 105
Cold-EEZE® Business [Member]
Payment of principal and accrued interest	$ 1,553
Cold-EEZE® Business [Member] \| Investors [Member]
Warrants aggregate exercise price	$ 69
Secured Promissory Notes [Member]
Debt instruments principal amount, maximum limit		$ 3,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Transactions Affecting Stockholders' Equity (Details Narrative) - USD ($)			6 Months Ended
	Jun. 12, 2017	Jul. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	May 24, 2016	Dec. 11, 2015	May 05, 2010
Common stock, shares authorized			50,000,000		50,000,000
Preferred stock, shares authorized			1,000,000		1,000,000
Preferred stock, par value			$ 0.0005		$ 0.0005
Common stock right's exercise price							$ 1.35
Equity method investment ownership percentage			50.00%
Stock option granted			600,000
Common stock option exercisable, per share			$ 2.00
Stock option, expected life			4 years 6 months
Weighted average risk rate			1.81%
Stock option, dividend yield			0.00%
Stock option, expected volatility			44.51%
Stock option, exercised			90,000
Proceeds from stock option exercised			$ 102,000
Common stock, shares issued			26,454,593		26,313,593
Employees [Member]
Stock option granted			600,000	600,000
Stock option vesting period				4 years
2015 Equity Line of Credit [Member] \| Dutchess [Member]
Stock issued during period shares		3,200,000
Maximum number of shares of draw down notice		500,000
Derivative transaction, conditions description			The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).
Number of shares beneficially held maximum percentage			4.99%
Available for sale, shares			$ 2,450,000
Stock Purchase Agreement [Member]
Equity method investment ownership percentage	6.20%
Options outstanding - shares	17,221,776
Common stock, shares purchased	1,061,980
Stock Purchase Agreement [Member] \| Leventhal Holders [Member]
Consideration paid	$ 1,858,465
Share price	$ 1.75
Chairman and Chief Executive Officer [Member] \| Rights Agreement [Member]
Equity method investment ownership percentage required for rights exercisable under right agreement			20.00%
Stockholder Rights Plan [Member]
Common stock right's exercise price			$ 45
Equity method investment ownership percentage required for rights exercisable under right agreement			15.00%
Percentage of discount on exercise of right			50.00%
Rights agreement expiration date			Jun. 18, 2024
2010 Equity Compensation Plan [Member]
Plan provides total number of shares of common stock issued						700,000		3,200,000
1997 Equity Compensation Plan [Member]
Plan provides total number of shares of common stock issued								900,000
2010 Plan [Member]
Options outstanding - shares			2,209,000
Available for grant, shares			133,659
2010 Directors' Equity Compensation Plan [Member]
Number of shares issued during period			425,000
Common stock, shares issued			147,808

XML 37 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Net operating loss carry-forwards					$ 47,100
Additional net operating loss carry-forwards					$ 22,100
Estimated federal and state income taxes to discontinued operations	$ (10)		$ 26,339
Income tax benefit from continuing operations			(18,123)
Cold-EEZE® Business [Member]
Income tax liability arising from taxable gain	$ 19,500		19,500
Income tax expense arising from sale			1,300
Estimated federal and state income taxes to discontinued operations			19,500
Income tax benefit from continuing operations			$ 18,123
Domestic Tax Authority [Member]
Operating loss carry forwards expiration dates description					Expire beginning for the year ended December 31, 2020 through 2036
State and Local Jurisdiction [Member]
Operating loss carry forwards expiration dates description					Expire beginning for the year ended December 31, 2020 through 2036

XML 38 R27.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Escrow deposit	$ 5,000
Mylan and Escrow Agent [Member] \| Escrow Agreement [Member]
Escrow deposit	$ 5,000
Escrow receivable, description	If, on the 18th month anniversary of the closing date, there are funds remaining in the escrow account, then the escrow account will be reduced by the difference, if a positive number, of (i) $2.5 million minus (ii) the aggregate amount of all escrow claims asserted by Mylan prior to this date that have either been paid out of the escrow account or are pending as of such date, and, within two business days of such date, the Escrow Agent will disburse such difference, if a positive number, to us. Within two business days of the second anniversary of the closing date, the Escrow Agent will release any funds remaining in the escrow account to us minus any amounts being reserved for escrow claims asserted by Mylan prior to such date. Upon the resolution of any pending escrow claims, the Escrow Agent will, within two business days of receipt of joint instructions or a final order from a court (as described in the Escrow Agreement) disburse such reserved amount to the parties entitled to such funds.
Agreement termination date	Mar. 29, 2022

XML 39 R28.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Estimated Future Minimum Obligations (Details) - Employment Contracts [Member] $ in Thousands	Jun. 30, 2017 USD ($)
2017	$ 338
2018	675
2019
2020
2021
Total	$ 1,013

XML 40 R29.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Details Narrative) - shares	3 Months Ended		6 Months Ended
Earnings (Loss) Per Share (Details Narrative) - shares	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Options and warrants outstanding to acquire shares			2,209,000	1,706,500
Anti diluted shares	641,754	276,165	650,190	244,112

XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 72 219 1 false 35 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://prophaselabs.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://prophaselabs.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://prophaselabs.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://prophaselabs.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Business Sheet http://prophaselabs.com/role/OrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE?? Business Sheet http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusiness Discontinued Operations, Sale of the Cold-EEZE?? Business Notes 9 false false R10.htm 00000010 - Disclosure - Secured Promissory Notes and Other Obligations Notes http://prophaselabs.com/role/SecuredPromissoryNotesAndOtherObligations Secured Promissory Notes and Other Obligations Notes 10 false false R11.htm 00000011 - Disclosure - Transactions Affecting Stockholders' Equity Sheet http://prophaselabs.com/role/TransactionsAffectingStockholdersEquity Transactions Affecting Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Income Taxes Sheet http://prophaselabs.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://prophaselabs.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Earnings (Loss) Per Share Sheet http://prophaselabs.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE?? Business (Tables) Sheet http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusinessTables Discontinued Operations, Sale of the Cold-EEZE?? Business (Tables) Tables http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusiness 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies (Tables) Sheet http://prophaselabs.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://prophaselabs.com/role/CommitmentsAndContingencies 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies - Components of Inventory (Details) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies-ComponentsOfInventoryDetails Summary of Significant Accounting Policies - Components of Inventory (Details) Details 20 false false R21.htm 00000021 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE?? Business (Details Narrative) Sheet http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusinessDetailsNarrative Discontinued Operations, Sale of the Cold-EEZE?? Business (Details Narrative) Details http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusinessTables 21 false false R22.htm 00000022 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE?? Business - Schedule of Proceeds from Sale of Business (Details) Sheet http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusiness-ScheduleOfProceedsFromSaleOfBusinessDetails Discontinued Operations, Sale of the Cold-EEZE?? Business - Schedule of Proceeds from Sale of Business (Details) Details 22 false false R23.htm 00000023 - Disclosure - Discontinued Operations, Sale of the Cold-EEZE?? Business - Schedule of Operating Results of Discontinued Operations (Details) Sheet http://prophaselabs.com/role/DiscontinuedOperationsSaleOfCold-eezeBusiness-ScheduleOfOperatingResultsOfDiscontinuedOperationsDetails Discontinued Operations, Sale of the Cold-EEZE?? Business - Schedule of Operating Results of Discontinued Operations (Details) Details 23 false false R24.htm 00000024 - Disclosure - Secured Promissory Notes and Other Obligations (Details Narrative) Notes http://prophaselabs.com/role/SecuredPromissoryNotesAndOtherObligationsDetailsNarrative Secured Promissory Notes and Other Obligations (Details Narrative) Details http://prophaselabs.com/role/SecuredPromissoryNotesAndOtherObligations 24 false false R25.htm 00000025 - Disclosure - Transactions Affecting Stockholders' Equity (Details Narrative) Sheet http://prophaselabs.com/role/TransactionsAffectingStockholdersEquityDetailsNarrative Transactions Affecting Stockholders' Equity (Details Narrative) Details http://prophaselabs.com/role/TransactionsAffectingStockholdersEquity 25 false false R26.htm 00000026 - Disclosure - Income Taxes (Details Narrative) Sheet http://prophaselabs.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://prophaselabs.com/role/IncomeTaxes 26 false false R27.htm 00000027 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://prophaselabs.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://prophaselabs.com/role/CommitmentsAndContingenciesTables 27 false false R28.htm 00000028 - Disclosure - Commitments and Contingencies - Schedule of Estimated Future Minimum Obligations (Details) Sheet http://prophaselabs.com/role/CommitmentsAndContingencies-ScheduleOfEstimatedFutureMinimumObligationsDetails Commitments and Contingencies - Schedule of Estimated Future Minimum Obligations (Details) Details 28 false false R29.htm 00000029 - Disclosure - Earnings (Loss) Per Share (Details Narrative) Sheet http://prophaselabs.com/role/EarningsLossPerShareDetailsNarrative Earnings (Loss) Per Share (Details Narrative) Details http://prophaselabs.com/role/EarningsLossPerShare 29 false false All Reports Book All Reports prph-20170630.xml prph-20170630.xsd prph-20170630_cal.xml prph-20170630_def.xml prph-20170630_lab.xml prph-20170630_pre.xml true true ZIP 47 0001493152-17-008961-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-008961-xbrl.zip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end